128 results on '"Feiterna-Sperling C"'
Search Results
2. Guidelines and practice of breastfeeding in women living with HIV—Results from the European INSURE survey.
- Author
-
Keane, A., Lyons, F., Aebi‐Popp, K., Feiterna‐Sperling, C., Lyall, H., Martínez Hoffart, A., Scherpbier, H., Thorne, C., Albayrak Ucak, H., and Haberl, A.
- Subjects
HIV-positive persons ,MOTHERS ,BREASTFEEDING promotion ,SURVEYS ,HIGHLY active antiretroviral therapy ,BREASTFEEDING - Abstract
Introduction: Antiretroviral therapy (ART) is integral to HIV prevention, including averting vertical transmission. The World Health Organization (WHO) recommends ART and breastfeeding for all women living with HIV for at least 12 months post‐partum [1, 2]. Much of the data on HIV transmission through breastfeeding comes from low‐resource settings, with a paucity of data on breastfeeding‐related HIV transmission in women living with HIV in other settings. Women Against Viruses in Europe (WAVE), part of the European AIDS Clinical Society (EACS), aims to improve the standard of care for women living with HIV and sought to gain an understanding of breastfeeding guidelines and practice in women living with HIV across Europe. Methods: A steering group convened by WAVE developed a survey to collate information on breastfeeding trends, practice, and guideline recommendations for women living with HIV in Europe and to establish interest in becoming involved in a collaborative breastfeeding network. The survey was disseminated to 31 countries in March 2022. Results: In total, 25 eligible responses were received: 23/25 (92%) countries have HIV and pregnancy guidelines; 23/23 (100%) guidelines refer specifically to breastfeeding; 12/23 (52%) recommend against breastfeeding; 11/23 (48%) offer an option if certain criteria are met; 12/25 (48%) reported that the number of women living with HIV who breastfeed is increasing; 24/25 (96%) respondents were interested in joining a network on breastfeeding in women living with HIV. Conclusions: Recommendations vary, and nearly half of the guidelines recommend against breastfeeding. Many countries report an increase in breastfeeding. WAVE will establish a collaborative network to bridge data gaps, conduct research, and improve support for women living with HIV who choose to breastfeed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Erratum zu: Diagnostik und Therapie der Syphilis. Aktualisierung der S2k-Leitlinie 2020 der Deutsche STI-Gesellschaft (DSTIG) in Kooperation mit folgenden Fachgesellschaften: DAIG, dagnä, DDG, DGA, DGGG, DGHM, DGI, DGN, DGPI, DGU, RKI
- Author
-
Schöfer, H., Enders, M., Esser, S., Feiterna-Sperling, C., Hagedorn, H.-J., Magistro, G., Mayr, C., Münstermann, D., Hahn, K., Jansen, K., Klein, M., Krause, W., Maschke, M., Ochsendorf, F. R., Osowski, S., Petry, K. U., Potthoff, A., Rieg, S., Sing, A., Stücker, M., Weberschock, T., Werner, R. N., and Brockmeyer, N. H.
- Published
- 2020
- Full Text
- View/download PDF
4. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study
- Author
-
Chappell, E., Riordan, A., Jourdain, G., Soriano-Arandes, A., Ene, L., Scherpbier, H., Warszawski, J., Collins, I., Smit, C., Marques, L., Klein, N., Guillén, S., Judd, A., Thorne, C., Goodall, R., Königs, C., Spoulou, V., Prata, F., Goetghebuer, T., Chiappini, E., Galli, L., Naver, L., Giaquinto, C., Gibb, D., Marczynska, M., Okhonskaia, L., Klimkait, T., Lallemant, M., Ngo-Giang-Huong, N., Kiseleva, G., Malyuta, R., Volokha, A., Hainaut, M., Delforge, M., Le Chenadec, J., Ramos, E., Dialla, O., Wack, T., Laurent, C., Ait Si Selmi, L., Leymarie, I., Ait Benali, F., Brossard, M., Boufassa, L., Floch-Tudal, C., Firtion, G., Hau, I., Chace, A., Bolot, P., Blanche, S., Levine, M., Bicëtre, L., Fourcade, C., Heller-Roussin, B., Runel-Belliard, C., Tricoire, J., Chirouze, C., Reliquet, V., Brouard, J., Kebaili, K., Fialaire, P., Lalande, M., Schultze-Strasser, S., Baumann, U., Niehues, T., Neubert, J., Kobbe, R., Berlin, C., Feiterna-Sperling, C., Buchholz, B., Notheis, G., de Martino, M., Angelo Tovo, P., Patrizia, O., Larovere, D., Ruggeri, M., Faldella, G., Baldi, F., Badolato, R., Montagnani, C., Venturini, E., Lisi, C., Di Biagio, A., Taramasso, L., Giacomet, V., Erba, P., Esposito, S., Lipreri, R., Salvini, F., Tagliabue, C., Cellini, M., Bruzzese, E., Lo Vecchio, A., Rampon, O., Donà, D., Romano, A., Dodi, I., Maccabruni, A., Consolini, R., Bernardi, S., Tchidjou Kuekou, H., Genovese, O., Olmeo, P., Cristiano, L., Mazza, A., Gabiano, C., Garazzino, S., Pellegatta, A., Pajkrt, D., Weijsenfeld, A., de Boer CG, Jurriaans, S., Back, N., Zaaijer, H., Berkhout, B., Cornelissen, M., Schinkel, C., Wolthers, K., Fraaij, P., van Rossum AMC, van der Knaap LC, Visser, E., Koopmans, M., van Kampen JJA, Pas, S., Henriet, S., van de Flier, M., van Aerde, K., Strik-Albers, R., Rahamat-Langendoen, J., Stelma, F., Schölvinck, E., de Groot-de Jonge, H., Niesters, H., van Leer-Buter CC, Knoester, M., Bont, L., Geelen, S., Wolfs, T., Nauta, N., Ang, C., van Houdt, R., Pettersson, A., Vandenbroucke-Grauls, C., Reiss, P., Bezemer, D., van Sighem AI, Wit, F., Boender, T., Zaheri, S., Hillebregt, M., de Jong, A., Bergsma, D., Grivell, S., Jansen, A., Raethke, M., Meijering, R., de Groot, L., van den Akker, M., Bakker, Y., Claessen, E., El Berkaoui, A., Koops, J., Kruijne, E., Lodewijk, C., Munjishvili, L., Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Rutkens, T., Schoorl, M., Timmerman, A., Tuijn, E., Veenenberg, L., van der Vliet, S., Wisse, A., Woudstra, T., Tuk, B., Popielska, J., Pokorska-Śpiewak, M., Ołdakowska, A., Zawadka, K., Coupland, U., DorobaLaura Marques, M., Teixeira, C., Fernandes, A., Voronin, E., Miloenko, M., Labutina, S., Tomás Ramos, J., Prieto, L., Luisa Navarro, M., Saavedra, J., Santos, M., Angeles Muñoz, M., Ruiz, B., Mc Phee CF, de Ory SJ, Alvarez, S., Ángel Roa, M., Beceiro, J., Martínez, J., Badillo, K., Apilanez, M., Pocheville, I., Garrote, E., Colino, E., Gómez Sirvent, J., Garzón, M., Román, V., Montesdeoca, A., Mateo, M., José Muñoz, M., Angulo, R., Neth, O., Falcón, L., Terol, P., Luis Santos, J., Moreno, D., Lendínez, F., Grande, A., José Romero, F., Lillo, M., Losada, B., Herranz, M., Bustillo, M., Guerrero, C., Collado, P., Antonio Couceiro, J., Pérez, A., Isabel Piqueras, A., Bretón, R., Segarra, I., Gavilán, C., Jareño, E., Montesinos, E., Dapena, M., Álvarez, C., Gloria Andrés, A., Marugán, V., Ochoa, C., Alfayate, S., Isabel Menasalvas, A., de Miguel, E., Aebi-Popp, K., Asner, S., Aubert, V., Battegay, M., Baumann, M., Bernasconi, E., Böni, J., Brazzola, P., Bucher, H., Calmy, A., Cavassini, M., Ciuffi, A., Duppenthaler, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Francini, K., Furrer, H., Fux, C., Grawe, C., Günthard, H., Haerry, D., Hasse, B., Hirsch, H., Hoffmann, M., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kovari, H., Kouyos, R., Ledergerber, B., Martinetti, G., de Tejada BM, Metzner, K., Müller, N., Nicca, D., Paioni, P., Pantaleo, G., Polli, C., Posfay-Barbe, K., Rauch, A., Rudin, C., Schmid, P., Scherrer, A., Speck, R., Tarr, P., Thanh Lecompte, M., Trkola, A., Vernazza, P., Wagner, N., Wandeler, G., Weber, R., Wyler, C., Yerly, S., Techakunakorn, P., Hansudewechakul, R., Kham, C., Wanchaitanawong, V., Theansavettrakul, S., Sai, M., Nanta, S., Ngampiyaskul, C., Phanomcheong, S., Hongsiriwon, S., Karnchanamayul, W., Kwanchaipanich, R., Kanjanavanit, S., Kamonpakorn, N., Nantarukchaikul, M., Layangool, P., Mekmullica, J., Lucksanapisitkul, P., Watanayothin, S., Lertpienthum, N., Warachit, B., Hanpinitsak, S., Potchalongsin, S., Thanasiri, P., Krikajornkitti, S., Attavinijtrakarn, P., Srirojana, S., Bunjongpak, S., Puangsombat, A., Na-Rajsima, S., Ananpatharachai, P., Akarathum, N., Phuket, V., Lawtongkum, W., Kheunjan, P., Suriyaboon, T., Saipanya, A., Than-In-At, K., Jaisieng, N., Suaysod, R., Chailoet, S., Naratee, N., Kawilapat, S., Kaleeva, T., Baryshnikova, Y., Soloha, S., Bashkatova, N., Raus, I., Glutshenko, O., Ruban, Z., Prymak, N., Bailey, H., Bamford, A., Butler, K., Doerholt, K., Doherty, C., Foster, C., Francis, K., Harrison, I., Kenny, J., Letting, G., Mcmaster, P., Murau, F., Nsangi, E., Peters, H., Prime, K., Shackley, F., Shingadia, D., Storey, S., Tudor-Williams, G., Turkova, A., Welch, S., Jeannie Collins, I., Cook, C., Crichton, S., Dobson, D., Fairbrother, K., M Gibb D, Harper, L., Le Prevost, M., Van Looy, N., Walsh, A., Thrasyvoulou, L., Bernatoniene, J., Manyika, F., Sharpe, G., Subramaniam, B., Sloper, K., Fidler, K., Hague, R., Price, V., Clapson, M., Flynn, J., Cardoso, A., Abou-Rayyah, M., Gurtin, D., Yeadon, S., Segal, S., Ball, C., Hawkins, S., Dowie, M., Bandi, S., Percival, E., Eisenhut, M., Duncan, K., Clough, S., Anguvaa, L., Conway, S., Flood, T., Pickering, A., Murphy, C., Daniels, J., Lees, Y., Thompson, F., Williams, B., Pope, S., Cliffe, L., Smyth, A., Southall, S., Freeman, A., Freeman, H., Christie, S., Gordon, A., Rogahn, D., Clarke, L., Jones, L., Offerman, B., Greenberg, M., Benson, C., Ibberson, L., Faust, S., Hancock, J., Sharland, M., Lyall, H., Monrose, C., Seery, P., Menson, E., Callaghan, A., Bridgwood, A., Evans, J., Blake, E., Yannoulias, A., Critchton, S., Duff, C., Gomezpena, D., Lundin, R., Mangiarini, L., Nardone, A., Posfay Barbe, Klara, Universidad de Alcalá - University of Alcalá (UAH), Department of Sciences for Woman and Child's Health, Università degli Studi di Firenze = University of Florence (UniFI), Épidémiologie clinique, santé mère-enfant et VIH en Asie du Sud-Est (IRD_PHPT), Harvard University-Chiang Mai University (CMU), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de Saint-Denis [Ile-de-France], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Pédiatrie Médicale [Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'hématologie : Immuno-Hématologie pédiatrique et transplantation de moelle osseuse, Hôpital Debrousse, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universitätsklinikum Frankfurt, Infectious Diseases, San Martino Hospital, Università degli studi di Genova = University of Genoa (UniGe), Department of Maternal and Pediatric Sciences, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Maternal-Infantile Department, Unit of Paediatrics and Oncohematology, University Hospital of Parma, Department of Infectious Diseases, IRCCS S. Matteo, Department of Paediatrics, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Dipartimento di Ingegneria [Benevento], Università degli Studi del Sannio, University of Twente, Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Laboratory for Infectious Diseases and Perinatal Screening, Center for Infectious Disease Control, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Architecture et réactivité de l'ARN (ARN), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Synthèse, Structure et Propriétés de Matériaux Fonctionnels (STEP), SYstèmes Moléculaires et nanoMatériaux pour l’Energie et la Santé (SYMMES), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Département Interfaces pour l'énergie, la Santé et l'Environnement (DIESE), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Stichting HIV Monitoring, Universidade Federal do Ceará = Federal University of Ceará (UFC), Departamento de Química Orgánica, Universidade de Vigo, Polytechnical University of Valencia, Fac Biol, Dept Genet, Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU), Service des maladies infectieuses, Hôpitaux Universitaires de Genève (HUG), University of Basel (Unibas), Dysfonctions métaboliques et diabètes: Mécanismes et approches thérapeutiques, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-IFR50-Institut National de la Santé et de la Recherche Médicale (INSERM), University Heart Centre Freiburg - Bad Krozingen, Prapokklao Hospital [Chanthaburi, Thailand], Nakornping Hospital [Chiang Mai, Thailand], Samutsakhon Hospital [Samutsakhon, Thailand], Kalasin Hospital [Kalasin, Thailand], Sanpatong Hospital [Chiang Mai, Thailand], Chiang Mai University (CMU), Microbiology Department, St. Jame's Hospital, University of Edinburgh, Infectious Diseases and Microbiology Unit, Great Ormond Street Hospital for Children [London] (GOSH)-Institute of Child Health, European Synchrotron Radiation Facility (ESRF), Centre for Ecology and Hydrology [Bangor] (CEH), Natural Environment Research Council (NERC), Jet Propulsion Laboratory (JPL), NASA-California Institute of Technology (CALTECH), University of London [London], London South Bank University (LSBU), Dipartimento di Pediatria, Azienda Ospedaliera di Padova, Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord, Florence University, Harvard University [Cambridge]-Chiang Mai University (CMU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), University of Genoa (UNIGE), Catholic University of Rome, University of Twente [Netherlands], Institut de Chimie du CNRS (INC)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), University of the Basque Country [Bizkaia] (UPV/EHU), Université Nice Sophia Antipolis (... - 2019) (UNS), Pediatrics, Virology, Chappell, Elizabeth, Riordan, Andrew, Jourdain, Gonzague, Soriano-Arandes, Antoni, Ene, Luminita, J Scherpbier, Henriette, Warszawski, Josiane, J Collins, Intira, Smit, Colette, Marques, Laura, Klein, Nigel, Guillén, Sara, Judd, Ali, Thorne, Claire, Goodall, Ruth, Königs, Christoph, Spoulou, Vana, Prata, Filipa, Goetghebuer, Tessa, Chiappini, Elena, Galli, Luisa, Naver, Lar, Giaquinto, Carlo, M Gibb, Diana, Marczynska, Magdalena, Okhonskaia, Liubov, Klimkait, Thoma, Lallemant, Marc, Ngo-Giang-Huong, Nicole, Kiseleva, Galyna, Malyuta, Ruslan, Volokha, Alla, Hainaut, Marc, Delforge, Marc, Le Chenadec, Jerome, Ramos, Elisa, Dialla, Olivia, Wack, Thierry, Laurent, Corine, Ait Si Selmi, Lamya, Leymarie, Isabelle, Ait Benali, Fazia, Brossard, Maud, Boufassa, Leila, Floch-Tudal, Corinne, Firtion, Ghislaine, Hau, Isabelle, Chace, Anne, Bolot, Pascal, Blanche, Stéphane, Levine, Martine, Kremlin Bicëtre, Le, Fourcade, Corinne, Heller-Roussin, Brigitte, Runel-Belliard, Camille, Tricoire, Joëlle, Chirouze, Catherine, Reliquet, Véronique, Brouard, Jacque, Kebaili, Kamila, Fialaire, Pascale, Lalande, Muriel, Schultze-Strasser, Stephan, Baumann, U, Niehues, T, Neubert, J, Kobbe, R, Berlin, Charite, Feiterna-Sperling, C, Königs, C, Buchholz, B, Notheis, G, de Martino, Maurizio, Angelo Tovo, Pier, Patrizia, Osimani, Larovere, Domenico, Ruggeri, Maurizio, Faldella, Giacomo, Baldi, Francesco, Badolato, Raffaele, Montagnani, Carlotta, Venturini, Elisabetta, Lisi, Catiuscia, Di Biagio, Antonio, Taramasso, Lucia, Giacomet, Vania, Erba, Paola, Esposito, Susanna, Lipreri, Rita, Salvini, Filippo, Tagliabue, Claudia, Cellini, Monica, Bruzzese, Eugenia, LO VECCHIO, Andrea, Paediatric Infectious Diseases / Rheumatology / Immunology, Amsterdam institute for Infection and Immunity, AII - Infectious diseases, Amsterdam Reproduction & Development (AR&D), APH - Aging & Later Life, Infectious diseases, and Global Health
- Subjects
0301 basic medicine ,medicine.medical_treatment ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,HIV Infections ,Rate ratio ,Cohort Studies ,0302 clinical medicine ,Pregnancy ,Antiretroviral Therapy, Highly Active ,Prevalence ,030212 general & internal medicine ,Child ,poor immune response ,ddc:618 ,Immunosuppression ,Viral Load ,Hepatitis B ,Thailand ,3. Good health ,Europe ,Thailand/epidemiology ,Infectious Diseases ,Cohort ,Coinfection ,Female ,Cohort study ,Adult ,Microbiology (medical) ,viral suppression ,medicine.medical_specialty ,Adolescent ,Anti-HIV Agents ,antiretroviral therapy ,030106 microbiology ,Europe/epidemiology ,03 medical and health sciences ,children ,Acquired immunodeficiency syndrome (AIDS) ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Humans ,HIV ,Aged ,Settore MED/38 - Pediatria Generale e Specialistica ,business.industry ,Immunity ,medicine.disease ,HIV Infections/drug therapy/epidemiology ,CD4 Lymphocyte Count ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Anti-HIV Agents/therapeutic use ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Background In human immunodeficiency virus (HIV)–positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on antiretroviral therapy (ART) have been associated with increased risk of morbidity and mortality. We assessed the prevalence and outcomes of poor immune response (PIR) in children receiving suppressive ART. Methods Sixteen cohorts from the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) contributed data. Children Results Of 2318 children included, median age was 6.4 years and 68% had advanced/severe immunosuppression at ART initiation. At 1 year of VS, 12% had PIR. In multivariable analysis, PIR was associated with older age and worse immunological stage at ART start, hepatitis B coinfection, and residing in Thailand (all P ≤ .03). Rates of AIDS/death (95% confidence interval) per 100 000 person-years were 1052 (547, 2022) among PIR versus 261 (166, 409) among immune responders; rate ratio of 4.04 (1.83, 8.92; P < .001). Conclusions One in eight children in our cohort experienced PIR despite sustained VS. While the overall rate of AIDS/death was low, children with PIR had a 4-fold increase in risk of event as compared with immune responders.
- Published
- 2020
5. Positive Kappa‐Deleting Recombination Excision Circles (KREC) Newborn Screening in a Neonate With Intrauterine Exposure to Rituximab
- Author
-
Krüger, R., Borte, S., von Weizsäcker, K., Wahn, V., and Feiterna‐Sperling, C.
- Published
- 2018
- Full Text
- View/download PDF
6. HIV-Infektion und AIDS
- Author
-
Wahn, V., Feiterna-Sperling, C., Niehues, T., Grosch-Wörner, I., Lentze, Michael J., editor, Schulte, Franz J., editor, Schaub, Jürgen, editor, and Spranger, Jürgen, editor
- Published
- 2007
- Full Text
- View/download PDF
7. Die kindliche HIV-Infektion
- Author
-
Seel, K., Feiterna-Sperling, C., Grosch-Wörner, I., and Husstedt, I. W., editor
- Published
- 1998
- Full Text
- View/download PDF
8. Leitlinien zur antiretroviralen Therapie bei HIV-infizierten Kindern und Jugendlichen
- Author
-
NEUBERT, J., primary, NIEHUES, T., additional, BAUMANN, U., additional, BUCHHOLZ, B., additional, NOTHEIS, G., additional, WINTERGERST, U., additional, BLUME, J., additional, FEITERNA-SPERLING, C., additional, LAWS, H.-J., additional, LINDE, R., additional, and KÖNIGS, C., additional
- Published
- 2015
- Full Text
- View/download PDF
9. Low raltegravir transfer into the breastmilk of a woman living with HIV
- Author
-
Feiterna-Sperling, C., Bukkems, V.E., Teulen, M.J.A., Colbers, A.P., Feiterna-Sperling, C., Bukkems, V.E., Teulen, M.J.A., and Colbers, A.P.
- Abstract
Contains fulltext : 225330.pdf (Publisher’s version ) (Open Access)
- Published
- 2020
10. Safety, Efficacy, and Pharmacokinetic Analysis of Glecaprevir/Pibrentasvir in Pediatric Patients With Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection: Part 2 of the DORA Study
- Author
-
UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Jonas, M., Rhee, S, Kelly, D, Del Valle Segarra, A, Feiterna-Sperling, C, Gilmour, S, Gonzalez-Peralta, RP, Hierro, L, Leung, D.H., Ling, S.C., Lobzin, Y, Lobritto, S, Narkewicz, M.R, Sabharwal, V, Wen, J, Kei Lon, H, Marcinak, J., Topp, A, Tripathi, R, Sokal, Etienne, The Liver Meeting Digital Experience - AASLD, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Jonas, M., Rhee, S, Kelly, D, Del Valle Segarra, A, Feiterna-Sperling, C, Gilmour, S, Gonzalez-Peralta, RP, Hierro, L, Leung, D.H., Ling, S.C., Lobzin, Y, Lobritto, S, Narkewicz, M.R, Sabharwal, V, Wen, J, Kei Lon, H, Marcinak, J., Topp, A, Tripathi, R, Sokal, Etienne, and The Liver Meeting Digital Experience - AASLD
- Published
- 2020
11. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand
- Author
-
Goetghebuer T, Hainaut M, Van der Kelen E, Delforge M, Warszawski J, Le Chenadec J, Ramos E, Dialla O, Wack T, Laurent C, Selmi L, Leymarie I, Benali F, Brossard M, Boufassa L, Floch-Tudal C, Firtion G, Hau I, Chace A, Bolot P, Blanche S, Granier M, Labrune P, Lachassine E, Dollfus C, Levine M, Fourcade C, Heller-Roussin B, Runel-Belliard C, Tricoire J, Monpoux F, Chirouze C, Reliquet V, Brouard J, Kebaili K, Fialaire P, Lalande M, Mazingue F, Partisani M, Koenigs C, Schultze-Strasser S, Baumann U, Niehues T, Neubert J, Kobbe R, Feiterna-Sperling C, Buchholz B, Notheis G, Spoulou V, Tovo P, Galli L, Chiappini E, Patrizia O, Larovere D, Ruggeri M, Faldella G, Baldi F, Badolato R, Montagnani C, Venturini E, Lisi C, Di Biagio A, Taramasso L, Giacomet V, Erba P, Esposito S, Lipreri R, Salvini F, Tagliabue C, Cellini M, Bruzzese E, Lo Vecchio A, Rampon O, Dona D, Romano A, Dodi I, Maccabruni A, Consolini R, Bernardi S, Genovese O, Olmeo P, Cristiano L, Mazza A, Garazzino S, Pellegatta A, Pajkrt D, Scherpbier H, Weijsenfeld A, van der Plas A, Jurriaans S, Back N, Zaaijer H, Berkhout B, Cornelissen M, Schinkel C, Wolthers K, Fraaij P, van Rossum A, van der Knaap L, Visser E, Boucher C, Koopmans M, van Kampen J, Pas S, Henriet S, de Flier M, van Aerde K, Strik-Albers R, Rahamat-Langendoen J, Stelma F, Scholvinck E, de Groot-de Jonge H, Niesters H, van Leer-Buter C, Knoester M, Bont L, Geelen S, Wolfs T, Nauta N, Ang C, van Houdt R, Pettersson A, Vandenbroucke-Grauls C, Reiss P, Bezemer D, van Sighem A, Smit C, Wit F, Boender T, Zaheri S, Hillebregt M, de Jong A, Bergsma D, Grivell S, Jansen A, Raethke M, Meijering R, de Groot L, van den Akker M, Bakker Y, Claessen E, El Berkaoui A, Koops J, Kruijne E, Lodewijk C, Munjishvili L, Peeck B, Ree C, Regtop R, Ruijs Y, Rutkens T, Schoorl M, Timmerman A, Tuijn E, Veenenberg L, van der Vliet S, Wisse A, Woudstra T, Tuk B, Marczynska M, Oldakowska A, Popielska J, Coupland U, Doroba M, Marques L, Teixeira C, Fernandes A, Prata F, Ene L, Gingaras C, Radoi R, Okhonskaia L, Voronin E, Miloenko M, Labutina S, Soler-Palacin P, Antoinette Frick M, Perez-Hoyos S, Mur A, Lopez N, Mendez M, Mayol L, Vallmanya T, Calavia O, Garcia L, Coll M, Pineda V, Rius N, Rovira N, Duenas J, Fortuny C, Noguera-Julian A, Jose Mellado M, Escosa L, Garcia Hortelano M, Sainz T, Isabel Gonzalez-Tome M, Rojo P, Blazquez D, Tomas Ramos J, Prieto L, Guillen S, Luisa Navarro M, Saavedra J, Santos M, Angeles Munoz M, Ruiz B, Fernandez Mc Phee C, Jimenez de Ory S, Alvarez S, Angel Roa M, Beceiro J, Martinez J, Badillo K, Apilanez M, Pocheville I, Garrote E, Colino E, Gomez Sirvent J, Garzon M, Roman V, Montesdeoca A, Mateo M, Jose Munoz M, Angulo R, Neth O, Falcon L, Terol P, Luis Santos J, Moreno D, Lendinez F, Grande A, Jose Romero F, Perez C, Lillo M, Losada B, Herranz M, Bustillo M, Guerrero C, Collado P, Antonio Couceiro J, Perez A, Isabel Piqueras A, Breton R, Segarra I, Gavilan C, Jareno E, Montesinos E, Dapena M, Alvarez C, Gloria Andres A, Marugan V, Ochoa C, Alfayate S, Isabel Menasalvas A, de Miguel E, Naver L, Soeria-Atmadja S, Hagas V, Aebi-Popp K, Asner S, Aubert V, Battegay M, Baumann M, Bernasconi E, Boni J, Brazzola P, Bucher H, Calmy A, Cavassini M, Ciuffi A, Duppenthaler A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Francini K, Furrer H, Fux C, Grawe C, Gunthard H, Haerry D, Hasse B, Hirsch H, Hoffmann M, Hosli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kovari H, Kouyos R, Ledergerber B, Martinetti G, de Tejada M, Metzner K, Muller, Nicca D, Paioni P, Pantaleo G, Polli C, Posfay-Barbe K, Rauch A, Rudin C, Schmid P, Scherrer A, Speck R, Tarr P, Lecompte T, Trkola A, Vernazza P, Wagner N, Wandeler G, Weber R, Wyler C, Yerly S, Techakunakorn P, Prachanukroh C, Hansudewechakul R, Wanchaitanawong V, Theansavettrakul S, Nanta S, Ngampiyaskul C, Phanomcheong S, Hongsiriwon S, Karnchanamayul W, Chacheongsao B, Kwanchaipanich R, Kanjanavanit S, Prapinklao S, Kamonpakorn N, Nantarukchaikul M, Adulyadej B, Layangool P, Mekmullica J, Lucksanapisitkul P, Watanayothin S, Lertpienthum N, Warachit B, Hanpinitsak S, Potchalongsin S, Thanasiri P, Krikajornkitti S, Attavinijtrakarn P, Srirojana S, Bunjongpak S, Puangsombat A, Na-Rajsima S, Ananpatharachai P, Akarathum N, Phuket V, Lawtongkum W, Kheunjan P, Suriyaboon T, Saipanya A, Than-in-at K, Jaisieng N, Suaysod R, Chailoet S, Naratee N, Kawilapat S, Kaleeva T, Baryshnikova Y, Soloha S, Bashkatova N, Raus I, Glutshenko O, Ruban Z, Prymak N, Kiseleva G, Bailey H, Lyall H, Butler K, Doerholt K, Foster C, Klein N, Menson E, Riordan A, Shingadia D, Tudor-Williams G, Tookey P, Welch S, Collins I, Cook C, Dobson D, Fairbrother K, Gibb D, Judd A, Harper L, Parrott F, Tostevin A, Van Looy N, Walsh A, Scott S, Vaughan Y, Laycock N, Bernatoniene J, Finn A, Hutchison L, Sharpe G, Williams A, Lyall E, Seery P, Lewis P, Miles K, Subramaniam B, Hutchinson L, Ward P, Sloper K, Gopal G, Doherty C, Hague R, Price V, Bamford A, Bundy H, Clapson M, Flynn J, Novelli V, Ainsley-Walker P, Tovey P, Gurtin D, Garside J, Fall A, Porter D, Segal S, Ball C, Hawkins S, Chetcuti P, Dowie M, Bandi S, McCabe A, Eisenhut M, Handforth J, Roy P, Flood T, Pickering A, Liebeschuetz S, Kavanagh C, Murphy C, Rowson K, Tan T, Daniels J, Lees Y, Kerr E, Thompson F, Le Provost M, Cliffe L, Smyth A, Stafford S, Freeman A, Reddy T, Fidler K, Christie S, Gordon A, Rogahn D, Harris S, Collinson A, Jones L, Offerman B, Van Someren V, Benson C, Riddell A, O'Connor R, Brown N, Ibberson L, Shackley F, Faust S, Hancock J, Donaghy S, Prime K, Sharland M, Storey S, Gorman S, Monrose C, Walters S, Cross R, Broomhall J, Scott D, Stroobant J, Bridgwood A, McMaster P, Evans J, Gardiner T, Jones R, Gardiner K, European Pregnancy Paediat HIV Coh, Stichting HIV Monitoring, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department of Sciences for Woman and Child's Health, Florence University, Dipartimento di Pediatria, Azienda Ospedaliera di Padova, Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Pediatrics, and Virology
- Subjects
Male ,0301 basic medicine ,Time Factors ,HIV ,antiretroviral therapy ,children ,second-line ,switch ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,Drug Resistance ,INFANTS ,HIV Infections ,Cohort Studies ,chemistry.chemical_compound ,0302 clinical medicine ,Interquartile range ,Antiretroviral Therapy, Highly Active ,ADOLESCENTS ,Cumulative incidence ,Viral ,Treatment Failure ,030212 general & internal medicine ,Child ,ComputingMilieux_MISCELLANEOUS ,Antiretroviral therapy ,Children ,Second-line ,Switch ,Age Factors ,Anti-HIV Agents ,Child, Preschool ,Drug Resistance, Viral ,Drug Substitution ,Europe ,Female ,Humans ,Infant ,Reverse Transcriptase Inhibitors ,Thailand ,Viral Load ,Reverse-transcriptase inhibitor ,Immunosuppression ,OPEN-LABEL ,VIROLOGICAL FAILURE ,3. Good health ,Infectious Diseases ,Viral load ,medicine.drug ,Microbiology (medical) ,medicine.medical_specialty ,Efavirenz ,Nevirapine ,SCALE-UP ,Article ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Highly Active ,Preschool ,business.industry ,HIV-1 DRUG-RESISTANCE ,ADULTS ,030112 virology ,RANDOMIZED-TRIAL ,Regimen ,INFECTED CHILDREN ,VIRAL LOAD ,chemistry ,business - Abstract
Background. Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand.Methods. Children aged = 2 nucleoside reverse transcriptase inhibitors p[NRTIs] plus nonnucleoside reverse transcriptase inhibitor p[NNRTI] or boosted protease inhibitor p[PI]) were included. Switch to second-line was defined as (i) change across drug class (PI to NNRTI or vice versa) or within PI class plus change of >= 1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. Cumulative incidence of switch was calculated with death and loss to follow-up as competing risks.Results. Of 3668 children included, median age at ART initiation was 6.1 (interquartile range (IQR), 1.7-10.5) years. Initial regimens were 32% PI based, 34% nevirapine (NVP) based, and 33% efavirenz based. Median duration of follow-up was 5.4 (IQR, 2.9-8.3) years. Cumulative incidence of switch at 5 years was 21% (95% confidence interval, 20%-23%), with significant regional variations. Median time to switch was 30 (IQR, 16-58) months; two-thirds of switches were related to treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral load (VL) at ART start, and NVP-based initial regimens were associated with increased risk of switch.Conclusions. One in 5 children switched to a second-line regimen by 5 years of ART, with two-thirds failure related. Advanced HIV, older age, and NVP-based regimens were associated with increased risk of switch.
- Published
- 2017
12. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women
- Author
-
Grosch-Woerner, I, Puch, K, Maier, R F, Niehues, T, Notheis, G, Patel, D, Casteleyn, S, Feiterna-Sperling, C, Groeger, S, and Zaknun, D
- Published
- 2008
13. Erratum zu: Tuberkulosescreening bei asylsuchenden Kindern und Jugendlichen ≺ 15 Jahren in Deutschland: Stellungnahme der Arbeitsgruppe AWMF-Leitlinie Tuberkulose im Kindes- und Jugendalter: Diagnostik, Prävention und Therapie unter Federführung der Deutschen Gesellschaft für Pädiatrische Infektiologie
- Author
-
Ritz, N., Brinkmann, F., Feiterna-Sperling, C., Hauer, B., Haas, W., and Arbeitsgruppe AWMF-Leitlinie Tuberkulose im Kindes- und Jugendalter: Diagnostik, Prävention und Therapie
- Published
- 2016
- Full Text
- View/download PDF
14. HIV-Infektionen
- Author
-
Wintergerst, U, Baumann, U A, von Both, U, Buchholz, B, Feiterna-Sperling, C, Kobbe, R, Königs, C, Neubert, J, Niehues, T, Nothheis, G, Paioni, P, University of Zurich, DGPI - Deutsche Gesellschaft für Pädiatrische Infektiologie, Berner, Reinhard, Bialek, Ralf, Forster, Johannes, Härtel, Christoph, Heininger, Ulrich, Huppertz, Hans-Iko, Liese, Johannes G, Nadal, David, and Simon, Arne
- Subjects
10036 Medical Clinic ,610 Medicine & health - Published
- 2018
15. Sicherheit von Tenofovir während der Schwangerschaft: Frühes Wachstum und hämatologische Nebenwirkungen bei HIV-exponierten nicht-infizierten Kleinkindern
- Author
-
Seidel, V, additional, Weizsäcker, K, additional, Henrich, W, additional, Rancourt, RC, additional, Bührer, C, additional, Krüger, R, additional, and Feiterna-Sperling, C, additional
- Published
- 2019
- Full Text
- View/download PDF
16. HIV-Infektionen
- Author
-
DGPI - Deutsche Gesellschaft für Pädiatrische Infektiologie, Berner, Reinhard, Bialek, Ralf, Forster, Johannes, Härtel, Christoph, Heininger, Ulrich, Huppertz, Hans-Iko, Liese, Johannes G, Nadal, David, Simon, Arne, DGPI - Deutsche Gesellschaft für Pädiatrische Infektiologie, ( ), Berner, R ( Reinhard ), Bialek, R ( Ralf ), Forster, J ( Johannes ), Härtel, C ( Christoph ), Heininger, U ( Ulrich ), Huppertz, H ( Hans-Iko ), Liese, J G ( Johannes G ), Nadal, D ( David ), Simon, A ( Arne ), Wintergerst, U, Baumann, U A, von Both, U, Buchholz, B, Feiterna-Sperling, C, Kobbe, R, Königs, C, Neubert, J, Niehues, T, Nothheis, G, Paioni, P, DGPI - Deutsche Gesellschaft für Pädiatrische Infektiologie, Berner, Reinhard, Bialek, Ralf, Forster, Johannes, Härtel, Christoph, Heininger, Ulrich, Huppertz, Hans-Iko, Liese, Johannes G, Nadal, David, Simon, Arne, DGPI - Deutsche Gesellschaft für Pädiatrische Infektiologie, ( ), Berner, R ( Reinhard ), Bialek, R ( Ralf ), Forster, J ( Johannes ), Härtel, C ( Christoph ), Heininger, U ( Ulrich ), Huppertz, H ( Hans-Iko ), Liese, J G ( Johannes G ), Nadal, D ( David ), Simon, A ( Arne ), Wintergerst, U, Baumann, U A, von Both, U, Buchholz, B, Feiterna-Sperling, C, Kobbe, R, Königs, C, Neubert, J, Niehues, T, Nothheis, G, and Paioni, P
- Published
- 2018
17. Highlights der neuen Leitlinie zur Diagnostik und Therapie der Tuberkulose im Kindes- und Jugendalter
- Author
-
Brinkmann, F., primary and Feiterna-Sperling, C., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Positive Kappa-Deleting Recombination Excision Circles (KREC) Newborn Screening in a Neonate With Intrauterine Exposure to Rituximab
- Author
-
Krüger, R., primary, Borte, S., additional, von Weizsäcker, K., additional, Wahn, V., additional, and Feiterna-Sperling, C., additional
- Published
- 2017
- Full Text
- View/download PDF
19. Consensus-Based Guidelines for Diagnosis, Prevention and Treatment of Tuberculosis in Children and Adolescents
- Author
-
Feiterna-Sperling, C., Brinkmann, F., Adamczick, C., Ahrens, F., Barker, M., Berger, C., Berthold, L. D., Bogyi, M., von Both, U., Frischer, T., Haas, W., Hartmann, P., Hillemann, D., Hirsch, F. W., Kranzer, K., Kunitz, F., Maritz, E., Pizzulli, A., Ritz, N., Schlags, R., Spindler, T., Thee, S., Weizsaecker, K., Feiterna-Sperling, C., Brinkmann, F., Adamczick, C., Ahrens, F., Barker, M., Berger, C., Berthold, L. D., Bogyi, M., von Both, U., Frischer, T., Haas, W., Hartmann, P., Hillemann, D., Hirsch, F. W., Kranzer, K., Kunitz, F., Maritz, E., Pizzulli, A., Ritz, N., Schlags, R., Spindler, T., Thee, S., and Weizsaecker, K.
- Abstract
Recently, epidemiological data shows an increase of childhood tuberculosis in Germany. In addition to this, drug resistant tuberculosis becomes more frequent. Therefore, diagnosis, prevention and therapy in childhood and adolescence remain a challenge. Adult guidelines do not work for children, as there are age specific differences in manifestation, risk of progression and diagnostic as well as therapeutic pathways. The German Society for Pediatric Infectious Diseases (DGPI) has initiated a consensus-based (S2k) process and completed a paediatric guideline in order to improve and standardize care for children and adolescents with tuberculosis exposure, infection or disease. Updated dosage recommendations take age dependant pharmacokinetics in the treatment of drug sensitive but also drug resistant tuberculosis in account. In addition to this, there is a detailed chapter on perinatal exposure and disease as well as extrapulmonary manifestations.
- Published
- 2017
20. S2k-Leitlinie zur Diagnostik, Prävention und Therapie der Tuberkulose im Kindes- und Jugendalter
- Author
-
Feiterna-Sperling, C., additional, Brinkmann, F., additional, Adamczick, C., additional, Ahrens, F., additional, Barker, M., additional, Berger, C., additional, Berthold, L., additional, Bogyi, M., additional, von Both, U., additional, Frischer, T., additional, Haas, W., additional, Hartmann, P., additional, Hillemann, D., additional, Hirsch, F., additional, Kranzer, K., additional, Kunitz, F., additional, Maritz, E., additional, Pizzulli, A., additional, Ritz, N., additional, Schlags, R., additional, Spindler, T., additional, Thee, S., additional, and Weizsäcker, K., additional
- Published
- 2017
- Full Text
- View/download PDF
21. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
- Author
-
Green, H, Gibb, Dm, Walker, As, Pillay, D, Butler, K, Candeias, E, CASTELLI GATTINARA, G, Compagnucci, A, DELLA NEGRA, M, DE ROSSI, Anita, FEITERNA SPERLING, C, Giaquinto, Carlo, Harper, L, Levy, J, Saidi, Y, Wintergerst, U, and Paediatric European Network for the Treatment of AIDS
- Subjects
medicine.medical_specialty ,Adolescent ,HIV-1 INFECTION ,Anti-HIV Agents ,Immunology ,HIV Infections ,Growth ,Placebo ,Gastroenterology ,Zidovudine ,immune system diseases ,Abacavir ,Antiretroviral Therapy, Highly Active ,Internal medicine ,Drug Resistance, Viral ,medicine ,Humans ,Immunology and Allergy ,Child ,ACTIVE ANTIRETROVIRAL THERAPY, HIV-1-INFECTED CHILDREN, HIV-1 INFECTION, PENTA-5 TRIAL ,HIV-1-INFECTED CHILDREN ,PENTA-5 TRIAL ,ACTIVE ANTIRETROVIRAL THERAPY ,business.industry ,Infant ,virus diseases ,Lamivudine ,Viral Load ,Resistance mutation ,Virology ,Dideoxynucleosides ,CD4 Lymphocyte Count ,Regimen ,Treatment Outcome ,Infectious Diseases ,Nelfinavir ,Child, Preschool ,HIV-1 ,RNA, Viral ,Reverse Transcriptase Inhibitors ,business ,Viral load ,Follow-Up Studies ,medicine.drug - Abstract
OBJECTIVE: To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial. DESIGN: PENTA 5 was a 48-week randomised controlled trial comparing three dual nucleoside reverse transcriptase inhibitor (NRTI) combinations as part of first triple antiretroviral therapy (ART). METHODS: 128 ART-naïve children were randomised to zidovudine\lamivudine (n = 36), zidovudine\abacavir (45) or lamivudine\abacavir (47). Asymptomatic children (n = 55) were also randomised to nelfinavir or placebo; all other children received open-label nelfinavir. Analyses are intent-to-treat and adjusted for minor baseline imbalances and receipt of nelfinavir/placebo. RESULTS: Median follow-up was 5.8 years. By 5 years, 17 (47%), 28 (64%) and 18 (39%) children had changed their randomised NRTIs in the zidovudine\lamivudine, zidovudine\abacavir and lamivudine\abacavir groups respectively, but 18%, 50% and 50% of these changes were either early single drug substitutions for toxicity or switches with viral suppression (HIV-1 RNA < 400 copies/ml; e.g. to simplify regimen delivery). At 5 years, 55%/32% zidovudine\lamivudine, 50%/25% zidovudine\abacavir and 79%/63% lamivudine\abacavir had HIV-1 RNA < 400/< 50 copies/ml respectively (p = 0.03/p = 0.003). Mean increase in height-for-age 0.42, 0.68, 1.05 (p = 0.02); weight-for-age 0.03, 0.13, 0.75 (p = 0.02). Reverse transcriptase resistance mutations emerging on therapy differed between the groups: zidovudine\lamivudine (M41L, D67N, K70R, M184V, L210W, T215Y); zidovudine\abacavir (M41L, D67N, K70R, L210W, T215F/Y, K219Q); lamivudine\abacavir (K65R, L74V, Y115F, M184V). CONCLUSIONS: Five year data demonstrate that lamivudine\abacavir is more effective in terms of HIV-1 RNA suppression and growth changes, with lower rates of switching with detectable HIV-1 RNA than zidovudine\lamivudine or zidovudine\abacavir, and should be preferred as first-line NRTI backbone.
- Published
- 2007
22. Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman
- Author
-
Schalkwijk, S.J., Feiterna-Sperling, C., Weizsacker, K., Colbers, A., Buhrer, C., Greupink, R., Russel, F.G.M., Burger, D.M., Schalkwijk, S.J., Feiterna-Sperling, C., Weizsacker, K., Colbers, A., Buhrer, C., Greupink, R., Russel, F.G.M., and Burger, D.M.
- Abstract
Contains fulltext : 170835.pdf (publisher's version ) (Closed access)
- Published
- 2016
23. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation
- Author
-
Yin, D.E., Warshaw, M.G., Miller, W.C., Castro, H., Fiscus, S.A., Harper, L.M., Harrison, L.J., Klein, N.J., Lewis, J., Melvin, A.J., Tudor Williams, G., Mckinney, R.E., Brouwers, P., Costello, D., Ferguson, E., Fiscus, S., Hodge, J., Hughes, M., Jennings, C., Melvin, A., Mckinney, R., Mofenson, L., Warshaw, M., Smith, M., Spector, S., Stiehm, E., Toye, M., Yogev, R., Babiker, A., Compagnucci, A., De Rossi, A., Giaquinto, C., Darbyshire, J., Debré, M., Gibb, D., Harper, L., Harrison, L., Klein, N., Pillay, D., Saidi, Y., Walker, A., Brody, B., Hill, C., Lepage, P., Modlin, J., Poziak, A., Rein, M., Robb, M., Fleming, T., Vella, S., Kim, K., Bologna, R., Mecikovsky, D., Pineda, N., Sen, L., Mangano, A., Marino, S., Galvez, C., Deluchi, G., Zöhrer, B., Zenz, W., Daghofer, E., Pfurtscheller, K., Pabst, B., Gomez, M., Mcneil, P., Jervis, M., Whyms, I., Kwolfe, D., Scott, S., Mussi Pinhata MM, Issac, M., Cervi, M., Negrini, B., Matsubara, T., de Souza CB, Gabaldi, J., Oliveira, R., Sapia, M., Abreu, T., Evangelista, L., Pala, A., Fernandes, I., Farias, I., Melo M, D.F., Carreira, H., Lira, L., Della Negra, M., Queiroz, W., Lian, Y., Pacola, D., Pinto, J., Ferreira, F., Kakehasi, F., Martins, L., Diniz, A., Lobato, V., Diniz, M., Cleto, S., Costa, S., Romeiro, J., Dollfus, C., Tabone, M., Courcoux, M., Vaudre, G., Dehée, A., Schnuriger, A., Le Gueyades, N., De Bortoli, C., Méchinaud, F., Reliquet, V., Arias, J., Rodallec, A., André, E., Falconi, I., Le Pelletier, A., Monpoux, F., Cottalorda, J., Mellul, S., Lachassinne, E., Galimand, J., Rouzioux, C., Chaix, M., Benabadji, Z., Pourrat, M., Firtion, G., Rivaux, D., Denon, M., Boudjoudi, N., Nganzali, F., Krivine, A., Méritet, J., Delommois, G., Norgeux, C., Guérin, C., Floch, C., Marty, L., Hichou, H., Tournier, V., Faye, A., Le Moal, I., Sellier, M., Dehache, L., Damond, F., Leleu, J., Beniken, D., Alexandre Castor, G., Neubert, J., Niehues, T., Laws, H., Huck, K., Gudowius, S., Siepermann, K., Loeffler, H., Bellert, S., Ortwin, A., Notheis, G., Wintergerst, U., Hoffman, F., Werthmann, A., Seyboldt, S., Schneider, L., Bucholz, B., Feiterna Sperling, C., Peiser, C., Nickel, R., Schmitz, T., Piening, T., Müller, C., Warncke, G., Wigger, M., Neubauer, R., Butler, K., Chong, A., Boulger, T., Menon, A., O'Connell, M., Barrett, L., Rochford, A., Goode, M., Hayes, E., Mcdonagh, S., Walsh, A., Doyle, A., Fanning, J., O'Connor, M., Byrne, M., O'Sullivan, N., Hyland, E., Giacomet, V., Viganò, A., Colombo, I., Trabattoni, D., Berzi, A., Badolato, R., Schumacher, F., Bennato, V., Brusati, M., Sorlini, A., Spinelli, E., Filisetti, M., Bertulli, C., Rampon, O., Zanchetta, M., Mazza, A., Stringari, G., Rossetti, G., Bernardi, S., Martino, A., Castelli Gattinara, G., Palma, P., Pontrelli, G., Tchidjou, H., Furcas, A., Frillici, C., Mazzei, A., Zoccano, A., Concato, C., Duiculescu, D., Oprea, C., Tardei, G., Abaab, F., Mardarescu, M., Draghicenoiu, R., Otelea, D., Alecsandru, L., Matusa, R., Rugina, S., Ilie, M., Netescu, S., Florea, C., Voicu, E., Poalelungi, D., Belmega, C., Vladau, L., Chiriac, A., Ramos Amador JT, Gonzalez Tomé MI, Rojo Conejo, P., Fernandez, M., Delgado Garcia, R., Ferrari, J., Garcia Lopez, M., Mellado Peña MJ, Martin Fontelos, P., Jimenez Nacher, I., Muñoz Fernandez MA, Jimenez, J., García Torre, A., Penin, M., Pineiro Perez, R., Garcia Mellado, I., Finn, A., Lajeunesse, M., Hutchison, E., Usher, J., Ball, L., Dunn, M., Sharland, M., Doerholt, K., Storey, S., Donaghy, S., Chakraborty, R., Wells, C., Buckberry, K., Rice, P., Mcmaster, P., Butler, P., O'Connell C, R., Shenton, J., Haley, H., Orendi, J., Stroobant, J., Navarante, L., Archer, P., Mazhude, C., Scott, D., O'Connell, R., Wong, J., Boddy, G., Shackley, F., Lakshman, R., Hobbs, J., Ball, G., Kudesia, G., Bane, J., Painter, D., Sloper, K., Shah, V., Cheng, A., Aali, A., Ball, C., Hawkins, S., Nayagam, D., Waters, A., Doshi, S., Liebeschuetz, S., Sodiende, B., Shingadia, D., Wong, S., Swan, J., Shah, Z., Collinson, A., Hayes, C., King, J., O'Connor, K., Lyall, H., Fidler, K., Walters, S., Foster, C., Hamadache, D., Newbould, C., Monrose, C., Campbell, S., Yeung, S., Cohen, J., Martinez Allier, N., Melvin, D., Dodge, J., Welch, S., Tatum, G., Gordon, A., Kaye, S., Muir, D., Patel, D., Novelli, V., Moshal, K., Lambert, J., Flynn, J., Farrelly, L., Clapson, M., Spencer, L., Depala, M., Jacobsen, M., Segal, S., Pollard, A., Kelly, D., Yeadon, S., Ohene Kena, B., Peng, Y., Dong, T., Jeffries, K., Snelling, M., Smyth, A., Smith, J., Ward, B., Jungmann, E., Ryan, C., Swaby, K., Buckton, A., Smit, E., Abrams, E., Champion, S., Fernandez, A., Calo, D., Garrovillo, L., Swaminathan, K., Alford, T., Frere, M., Navarra, J., Borkowsky, W., Deygoo, S., Hastings, T., Akleh, S., Ilmet, T., Mohan, K., Bowen, G., Emmanuel, P., Lujan Zimmerman, J., Rodriguez, C., Johnson, S., Marion, A., Graisbery, C., Casey, D., Lewis, G., Guzman Cottrill, J., Croteau, R., Acevedo Flores, M., Gonzalez, M., Angeli, L., Fabregas, L., Valentin, P., Weiner, L., Contello, K., Holz, W., Butler, M., Nachman, S., Kelly, M., Ferraro, D., Rana, S., Reed, C., Yeagley, E., Malheiro, A., Roa, J., Neely, M., Kovacs, A., Homans, J., Rodriguez Lozano, Y., Puga, A., Talero, G., Sellers, R., Lawrence, R., Weinberg, G., Murante, B., Laverty, S., Deveikis, A., Batra, J., Chen, T., Michalik, D., Deville, J., Elkins, K., Marks, S., Jackson Alvarez, J., Palm, J., Fineanganofo, I., Keuth, M., Deveikis, L., Tomosada, W., Van Dyke, R., Alchediak, T., Silio, M., Borne, C., Bradford, S., Eloby Childress, S., Nguyen, K., Rathore, M., Alvarez, A., Mirza, A., Mahmoudi, S., Burke, M., Febo, I., Lugo, L., Santos, R., Church, J., Dunaway, T., Rodier, C., Flynn, P., Patel, N., Discenza, S., Donohoe, M., Luzuriaga, K., Picard, D., Kline, M., Paul, M., Shearer, W., Mcmullen, C., Chadwick, E., Cagwin, E., Kabat, K., Dieudonne, A., Palumbo, P., Johnson, J., Gaur, S., Cerracchio, L., Foca, M., Jurgrau, A., Vasquez Bonilla, S., Silva, G., Gershon, A., Sullivan, J., Bryson, Y., Frenkel, L., Nelson, J., Aboulker, J., Hadjou, G., Léonardo, S., Riault, Y., Saïdi, Y., Buck, L., Forcat, S., Horton, J., Johnson, D., Moore, S., Taylor, C., Collins, D., Buskirk, S., Kamara, P., Nesel, C., Johnson, M., Ferreira, A., Tutko, J., Sprenger, H., Britto, P., Powell, C., Dersimonian, R., Handelsman, E., Ananworanich, J., Belfrage, E., Blanche, S., Bohlin, A., Burger, D., Clayden, P., De Groot, R., Di Biagio, A., Grosch Wörner, I., Hainault, M., Lallemant, M., Levy, J., Marczynska, M., Mellado Pena MJ, Nadal, D., Naver, L., Peckham, C., Popieska, J., Rosado, L., Rosso, R., Rudin, C., Scherpbier, H., Stevanovic, M., Thorne, C., Tovo, P., Valerius, N., Poole, C., Cole, S., and Mcculloh, R.J.
- Subjects
CD4-Positive T-Lymphocytes ,Male ,medicine.medical_treatment ,HIV (FISIOLOGIA) ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Treatment failure ,Settore BIO/13 - Biologia Applicata ,Antiretroviral Therapy, Highly Active ,immunologic ,Child ,HIV ,child ,reconstitution ,treatment failure ,Adolescent ,Anti-HIV Agents ,CD4 Lymphocyte Count ,Child, Preschool ,Female ,Follow-Up Studies ,HIV-1 ,Humans ,Infant ,Infant, Newborn ,Follow up studies ,Immunosuppression ,medicine.medical_specialty ,Settore MED/17 - Malattie Infettive ,Antiretroviral Therapy ,World health ,Article ,Internal medicine ,medicine ,Highly Active ,Preschool ,Settore MED/04 - Patologia Generale ,business.industry ,Disease progression ,Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio ,Newborn ,Antiretroviral therapy ,Confidence interval ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Immunologic ,Reconstitution ,Pediatrics, Perinatology and Child Health ,Immunology ,business - Abstract
BACKGROUND: Quantifying pediatric immunologic recovery by highly active antiretroviral therapy (HAART) initiation at different CD4 percentage (CD4%) and age thresholds may inform decisions about timing of treatment initiation. METHODS: HIV-1-infected, HAART-naive children in Europe and the Americas were followed from 2002 through 2009 in PENPACT-1. Data from 162 vertically infected children, with at least World Health Organization “mild” immunosuppression and CD4% RESULTS: Seventy-two percent of baseline immunosuppressed children recovered to normal within 4 years. Compared with “severe” immunosuppression, more children with “mild” immunosuppression (difference 36%, 95% confidence interval [CI]: 22% to 49%) or “advanced” immunosuppression (difference 20.8%, 95% CI: 5.8% to 35.9%) recovered a normal CD4%. For each 5-year increase in baseline age, the proportion of children achieving a normal CD4% declined by 19% (95% CI: 11% to 27%). Combining baseline CD4% and age effects resulted in >90% recovery when initiating HAART with “mild” immunosuppression at any age or “advanced” immunosuppression at age CONCLUSIONS: Initiating HAART at higher CD4% and younger ages maximizes potential for immunologic recovery. Guidelines should weigh immunologic benefits against long-term risks.
- Published
- 2014
24. Chirurgische Behandlung von Kindern mit zervikaler atypischer Mykobakteriose
- Author
-
Hofmann, VM, Pudszuhn, A, Feiterna-Sperling, C, and Olze, H
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Einleitung: Eine Lymphadenitis colli ist die häufigste Manifestation von atypischen Mykobakterien, die bei meist immunkompetenten Kindern zwischen einem und fünf Jahren auftritt. Die Diagnose kann nur über einen definitiven Erregernachweis gestellt werden. Die Lymphknotenexstirpation [for full text, please go to the a.m. URL], 84. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie
- Published
- 2013
- Full Text
- View/download PDF
25. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West
- Author
-
Giaquinto, C, Rampon, O, D'Elia, R, De Rossi, A, Grosch Worner, I, Feiterna Sperling, C, Schmitz, T, Casteleyn, S, Mok, J., de Jose, I, Bates, I, Larru, B, Pena, Jm, Garcia, Jg, Lopez, Jra, Garcia Rodriguez MC, Asensi Botet, F, Otero, Mc, Perez Tamarit, D, Suarez, G, Scherpbier, H, Kreyenbroek, M, Godfried, Mh, Nellen, Fj, Boer, K, Bohlin, Ab, Lindgren, S, Belfrage, E, Naver, L, Anzen, B, Lidman, K, Levy, J, Hainaut, M, Goetghebuer, T, Manigart, Y, Barlow, P, Ferrazin, A, Bassetti, D, De Maria, A, Bentivoglio, G, Ferrero, S, Gotta, C, Mur, A, Paya, A, Lopez Vilchez MA, Carreras, R, Valerius, Nh, Jimenez, J, Coll, O, Suy, A, Perez, Jm, Fortuny, C, Boguna, J, Caro, Mc, Canet, Y, Pardi, G, Ravizza, M, Guerra, B, Lanari, M, Bianchi, S, Bovicelli, L, Prati, E, Duse, Marzia, Scaravelli, G, Stegagno, M, De Santis, M, Savasi, V, Ferrazzi, E, Vigano, A, Giacomet, V, Probizer, Fr, Maccabruni, A, Bucceri, A, Rancilio, L, Alberico, S, Rabusin, M, Bernardon, M, Taylor, Gp, Lyall, Egh, Penn, Z, Buffolano, W, Tiseo, R, Martinelli, P, Sansone, M, Agangi, A, Tibaldi, C, and Marini, S.
- Published
- 2006
26. Konnatale Toxoplasmose
- Author
-
Feiterna-Sperling, C., additional
- Published
- 2014
- Full Text
- View/download PDF
27. Inter-laboratory comparison of HCV-RNA assay results: Implications for multi-centre research
- Author
-
Pembrey, L. Newell, M.-L. Tovo, P.-A. Van Drimmelen, H. Quinti, I. Furlini, G. Galli, S. Meliconi, M.G. Burns, S. Hallam, N. Sönnerborg, A. Cilia, G. Serrano, E. Laccetti, P. Portella, G. Polywka, S. Icardi, G. Bruzzone, B. Balbo, L. Alfarano, A. Amoroso, A. Asensi-Botet, F. Bona, G. Boucher, C. Buffolano, W. Butler, K. Cabero Roura, L. Bertran Sanges, J.M. Cigna, P. Ciria, L.M. Servera Ginard, C. Coll, O. Fortuny, C. Corrias, A. Ledda, R. Floris, S. De Maria, A. Echeverria, J. Cilla, G. Fabris, C. Feiterna Sperling, C. Grosch-Wörner, I. Fischler, B. Bohlin, A.-B. Fjaerli, H.A. Hannam, S. Mieli-Vergani, G. Hatzakis, A. Lanari, M. Papa, I. Venturi, V. Leon Leal, J.A. Lyall, H. Maccabruni, A. Pacati, I. Arlandi, L. Marcellini, M. Martin Fontelos, P. Mazza, A. Mok, J.Y.Q. Mûr, A. Viñolas, M. Palomba, E. Riva, C. Scolfaro, C. Paternoster, D.M. Grella, P. Casadei, A.M. Rojahn, A. Rosso, R. Bassetti, D. Ruiz Contreras, J. Manzanares, A. Ruiz Extremera, A. Souayah, H. Levy, J. Tudor-Williams, G. Vegnente, A. Wejstal, R. Norkrans, G. Zanetti, A. Tanzi, E. Zuccotti, G.V. Zuin, G. Saccani, B. Vigano, A.
- Abstract
To investigate whether it is appropriate to assume comparability of hepatitis virus C (HCV)-RNA results across laboratories in multi-centre studies, nine laboratories of the European Paediatric HCV Network participated in an international proficiency study of HCV-RNA assays. A panel of 12 samples of different dilutions and genotypes was sent to each laboratory and tested with qualitative and/or quantitative HCV-RNA assays according to local procedures. Commercial assays were used in seven laboratories and in-house assays in two. All six laboratories in which a commercial qualitative assay was used were proficient, as were four of six runs (in five laboratories) in which a commercial quantitative assay was used. The proficiency of the laboratories where in-house assays were used could not be assessed according to the VQC definition because of differences in the methods used. Overall, there were several false-negative results, but only one false-positive result with a quantitative assay and none with a qualitative assay. The false-negative results may have implications for the diagnosis of infection, and highlight the need for an antibody test to be performed at 18 months to confirm the absence of infection. The results of qualitative assays were generally consistent across laboratories but it was difficult to evaluate and compare the results of quantitative assays. Multivariate analysis of data collected in multi-centre studies should therefore allow for centre and/or assay used. © 2003 Wiley-Liss, Inc.
- Published
- 2003
28. High seroprevalence of human herpes virus 8 (HHV-8) antibodies among vertically HIV-infected pediatric patients living in Germany
- Author
-
Feiterna-Sperling, C., Königs, C., Notheis, G., Buchholz, B., Weizsaecker, K., Eberle, J., and Hofmann, J.
- Subjects
HIV infection in children -- Complications and side effects ,Herpes -- Risk factors -- Demographic aspects ,Herpesvirus diseases -- Risk factors -- Demographic aspects ,Health - Abstract
Background: Human herpes virus 8 (HHV‐8), a gamma herpes virus, is the etiological agent for Kaposi sarcoma (KS). HIV‐infected adults with advanced immunodeficiency are at risk. Prevalence data of HHV‐8 infection in HIV‐infected children living in non‐endemic areas are limited. Serologic studies indicate low seroprevalence rates of 3–4% for healthy children living in United States and Germany [1]. Purpose of the study: The aim of the study was to determine the seroprevalence of HHV‐8 antibodies among vertically HIV‐infected pediatric patients in Germany and to evaluate their association with age, gender, ethnicity, and other demographic factors. Methods: In 2012, a multi‐center cross‐sectional study was conducted in four University Hospitals in Germany. Stored frozen serum specimens obtained from vertically HIV‐infected children and adolescents were tested for antibodies against lytic and latent HHV‐8 antigens. Data on patients' demographic characteristics and medical history were recorded. Results: A total of 214 HIV‐infected children and adolescents (105 males, 109 females) were included. The median age was 10.2 years (range 1 months–22.6 years). A high proportion of these children (62%) was born in Western Europe, whereas 65% (139/214) of their mothers were born in countries outside Western Europe. The majoritiy (91%) of the children had been treated with highly active antiretroviral therapy and 55.2% (116/210) had a HIV‐viral load Conclusions: Vertically HIV‐infected pediatric patients living in Germany showed a high HHV‐8 seroprevalence of 23.8%. These rates were higher as expected in the normal pediatric population. The findings suggest that HHV‐8 infection occurred already in the first years of life., Reference Martro E, Bulterys M, Stewart JA, Spira TJ, Cannon MJ, Thacher TD, et al. Comparison of human herpesvirus 8 and Epstein‐Barr Virus seropositivity among children in areas endemic and [...]
- Published
- 2012
- Full Text
- View/download PDF
29. Postnatale Therapie der konnatalen Toxoplasmose: Ein Vergleich zweier unterschiedlicher Vorgehensweisen
- Author
-
Pohl-Schickinger, A., additional, Feiterna-Sperling, C., additional, Weizsäcker, K., additional, and Bührer, C, additional
- Published
- 2012
- Full Text
- View/download PDF
30. Leitlinie der Pädiatrische Arbeitsgemeinschaft AIDS (PAAD) e.V. zur antiretroviralen Therapie bei HIV-infizierten Kindern und Jugendlichen (2011)
- Author
-
Neubert, J., additional, Niehues, T., additional, Baumann, U., additional, Buchholz, B., additional, Notheis, G., additional, Wintergerst, U., additional, Blume, J., additional, Feiterna-Sperling, C., additional, Laws, H.-J., additional, Linde, R., additional, and Königs, C., additional
- Published
- 2012
- Full Text
- View/download PDF
31. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide
- Author
-
Weizsaecker, K, primary, Kurowski, M, additional, Hoffmeister, B, additional, Schürmann, D, additional, and Feiterna-Sperling, C, additional
- Published
- 2011
- Full Text
- View/download PDF
32. G5 - Leitlinien zur antiretroviralen Therapie bei HIV-infizierten Kindern und Jugendlichen
- Author
-
NEUBERT, J., NIEHUES, T., BAUMANN, U., BUCHHOLZ, B., NOTHEIS, G., WINTERGERST, U., BLUME, J., FEITERNA-SPERLING, C., LAWS, H.-J., LINDE, R., and KÖNIGS, C.
- Published
- 2015
- Full Text
- View/download PDF
33. Autorenverzeichnis
- Author
-
Graul-Neumann, L., Horn, D., Hübner, C., Huppke, P., König, R., Majewski, F., Meinecke, P., Pankau, R., Rosenbaum, T., Schnabel, D., Schuelke, M., Spranger, J., Theile, U., Tinschert, S., Wilichowski, E., Wollmann, H.A., Zenker, M., Bartmann, P., Bassler, D., Bührer, C., Flemmer, A.W., Forster, J., Franz, A., Gonser, M., Gortner, L., Groneck, P., Hentschel, R., Herting, E., Hoyme, U.B., Hummler, H., Jandeck, C., Jorch, G., Korinthenberg, R., Liese, J., Maier, R.F., Martius, J., Merkenschlager, A., Poets, C.F., Pohlandt, F., Roll, C., Roos, R., Roth, B., Schneider, K.T.M., Speer, Ch., Stopfkuchen, H., Teichmann, A., Thomas, W., Vetter, K., von der Wense, A., Zielen, S., Assmann, B., Hoffmann, G.F., Kölker, S., Lindner, M., Mönch, E., Santer, R., Spiekerkötter, U., Zschocke, J., Bauer, K., Böhles, H.-J., Sinclair, Jack, Jauch, K.W., Jochum, F., Kauth, Thomas, Koletzko, B., Krawinkel, M., Krohn, K., Mihatsch, Walter, Moß, A., Mühlebach, S., Verwied-Jorky, S., Wabitsch, M., Zimmer, K.-P., Albers, N., L'Allemand, D., Binder, G., Brämswig, J.H., Dörr, H.G., Grüters-Kieslich, A., Hauffa, B.P., Heger, S., Hiort, O., Holl, R., Holterhus, P.M., Köhler, B., Korsch, Eckhard, Kratzsch, J., Krude, H., Mohnike, K., Neu, A., Pfäffle, R., Richter-Unruh, A., Riepe, F.G., Simic-Schleicher, G., Schönau, E., Sinnecker, G., Sippell, W., Willgerodt, H., Wölfle, J., Wudy, S.A., Aygören-Pürsün, E., Bas, M., Baumann, U., Biedermann, T., Blume, J., Buchholz, B., Dückers, G., Dunsch, D., Edelhäuser, M., Ehl, S., Feiterna-Sperling, C., Funk, M., Hartmann, K., Königs, C., Kreuz, W., Krudewig, J., Laws, H.-J., Linde, R., Martinez-Saguer, I., Maurer, M., Nadal, David, Niehues, T., Notheis, G., Ott, H., Schulze, I., Wedi, B., Wintergerst, U., Bürk, G., Foeldvari, I., Frosch, M., Girschick, H., Gerhold, K., Guellac, N., Haas, J.P., Häfner, R., Häuser, W., Heiligenhaus, A., Hospach, T., Horneff, G., Huppertz, H.-I., Illhardt, A., Jansson, A.F., Kallinich, T., Michels, H., Mönkemöller, K., Neudorf, U., Richter, M., Schnöbel-Müller, E., Thon, A., Zernikow, B., Behnisch, W., Cario, H., Dickerhoff, R., Eber, S., Führer, M., Kohne, E., Kulozik, A.E., Kunz, J., Muckenthaler, M., Eberl, W., Gaedicke, G., Muntean, W., Streif, W., Beck, J.D., Berthold, F., Bielack, S., Calaminus, G., Claviez, A., Creutzig, U., Dirksen, U., Dworzak, M., Göbel, U., Graf, N., Grießmeier, B., Henze, G., Hero, B., Jürgens, H., Kaiser, U., Klingebiel, T., Koscielniak, E., Kramm, C., Langer, T., Lawrenz, B., Lehrnbecher, T., Leiss, U., Mentzel, H.-J., Minkov, M., Peitz, J., Placzek, R., Reinhardt, D., Reiter, A., Rutkowski, S., Schmittenbecher, P., Schneider, D.T., Schreiber-Gollwitzer, B.M., Schrappe, M., Schroten, H., Schröder, H.M., Schuster, V., von Schweinitz, D., Sörensen, N., Tallen, G., Timmermann, B., Warmuth-Metz, M., Weckesser, M., Wessel, L., Wirth, T., Wolff, J.E.A., Wößmann, W., Zehnhoff-Dinnesen, A. am, Apitz, C., Arnold, R., Baumgartner, H., Bennink, G., Bertram, H., Blankenburg, M., Bönner, G., von der Breek, J., Breuer, J., Buchhorn, R., Bürsch, J., Cesnjevar, R., Dähnert, I., Deisenhofer, I., Diller, G.-P., Doenst, T., Dubowy, K.-O., Eicken, A., Ewert, P., Fink, C., Franke, J., Gebauer, R., Gorenflo, M., Grabitz, Haas, N.A., Häusler, H.-J., Hager, A., Hebebrand, J., Henschel, W., Hirt, M., Hoeper, M.M., Hörer, J., Hofbeck, M., Horke, A., Hraska, V., Hulpke-Wette, M., šek, J. Janou, Jux, C., Kändler, L., Kandolf, R., Kaulitz, R., Kienast, W., Klaassen, S., Knirsch, W., Kramer, H.H., Kreuder, J.G., Kriebel, T., Läer, S., Laser, K.T., Lê, T.-P., Lewin, M.A.G., Lindinger, A., Mackenzie, C.R., Mebus, S., van der Mei, S.H., Miera, O., Ovroutski, S., Paul, T., Photiadis, J., Pozza, R. Dalla, Rickers, C., Rosendahl, W., Ruschewski, W., Sachweh, J.S., Schäfers, H.-J., Scheewe, J., Schirmer, K.-R., Schlensak, C., Schlez, M., Schmaltz, A.A., Schmitt, K., Schneider, H., Schneider, M.B., Schranz, D., Schreiber, C., Schulze-Neick, I., Sieverding, L.F.J., Singer, H., Stieh, J., Sreeram, N., Thies, W.-R., Thul, J., Trauzeddel, R., Tschöpe, C., Uebing, A., Ulmer, H.E., Vogel, M., Vogt, M., Weil, J., Wessel, A., Will, J.C., Wühl, E., Ballmann, M., Barben, J., Bauer, C.P., Bend, J., Berdel, D., Blankenstein, O., Bremer, W., Brunsmann, F., Buchholz, T., Bufe, A., Derichs, N., Eber, E., Friedrichs, F., Frischer, T., Gembruch, U., Gieler, U., Götz, M., Haas, W.H., Hamelmann, E., Hammer, J., Hellermann, M., Jacobeit, J., Jung, A., Keim, V., Kitz, R., Kleinheinz, A., Koletzko, S., Kopp, I., Kopp, M., Lau, S., Lauener, R., Loff, Magdorf, K., Muche-Borowski, C., Müller, F.-M., Müsken, H., Naehrlich, L., Nicolai, T., Nüßlein, Th., Paditz, E., Palm, Frau B., Paul, K., Pfeiffer-Auler, S., Pfeiffer-Kascha, Frau D., Posselt, H.-G., Przybilla, B., Räwer, H.-C., Ratjen, F., Reese, I., Riedler, J., Rietschel, E., Rose, M., Rossi, R., Ruëff, F., Schäfer, T., Schmidt, S., Schmitt-Grohé, S., Schulze, J., Schuster, A., Seidenberg, J., Sitter, H., Smaczny, C., Spindler, T., Staab, D., Stern, M., Strassburg, C.P., Strömer, K., Stuhrmann-Spangenberg, M., Szczepanski, R., Tacke, A., Tiedgen, M., Urschitz, M.S., Vagts, J., Vogelberg, C., Wahn, U., Walker, A., Werfel, T., Wildhaber, J.H., Zach, M., Zimmermann, Th., Ballauff, A., Bannert, N., Böhn, I., Buderus, S., Bufler, P., Burdelski, M., Gerner, P., Grosse, K.-P., Henker, J., Henneke, P., Huber, W., Lang, T., Lentze, M.J., Melter, M., Müller, T., Pfister, E.-D., Rodeck, B., Schmidt-Choudhury, A., Skopnik, H., Wirth, S., Witt, H., Bachmann, H., Dötsch, J., Ehrich, J.H., Fuchshuber, Arno, Hoppe, B., Hoyer, P.F., Kemper, M.J., Michalk, D., Müller, D., Müller-Wiefel, D.E., Pohl, M., Tönshoff, B., Zerres, K., Bast, T., Baumeister, F.A.M., Berner, R., Bode, H., Christen, H.J., Collmann, H., Ebinger, F., Eiffert, H., Evers, S., Gold, R., Groß, S., Hanefeld, F., Heinen, F., Holthausen, H., Hübner, A., Jacobi, G., Karch, D., Kauschke, C., Kerkhoff, G., Kiese-Himmel, C., Klepper, J., Kohlschütter, A., Korn-Merker, E., Krägeloh-Mann, I., Kropp, P., Kurlemann, G., de Langen-Müller, U., Lenard, H.G., Michael, Th., von Moers, A., Felderhoff-Müser, U., Nau, R., Neubauer, B.A., Neuhäuser, G., Neumann, K., Noterdaeme, M., Pothmann, R., Rating, D., Reitter, B., Rickels, E., Ritz, A.M., Rosenkötter, H., Schmitt, B., Stephani, U., Stöver, B., Tibussek, D., Trollmann, R., Trommer, G., Tuxhorn, I., Wohlrab, G., Boergen, K.P., Brosch, S., Delb, W., Frank, R., Herrmann, B., von Hofacker, N., de Camargo, O. Kraus, Kries, R.v., Michaelis, R., Papousek, M., Schlack, H.G., Schriever, J., Skrodzki, K., Straßburg, H.-M., Thyen, U., Becker, K., Fels, T., Fitze, G., Grasshoff-Derr, S., Göbel, P., Illing, P., Lieber, J., Schmidt, A., Wessel, L.M., Berthold, L.D., Hahn, G., Hirsch, W., Moritz, J.D., Schröder, C., Schumacher, R., Stegmann, J., Steinborn, M., Tietze, R., Wunsch, R., Deppe, W., Hermann, T., Kiosz, D., Leidig, E., Mayer, H., Oepen, J., Stachow, R., Ahrens, F., Frey, G., Huttegger, I., Preil, M.-L., Schmittenbecher, P.P., Traupe, H., Eberhardt, O., Hasler, C., Krauspe, R., Meenen, N.M., Meurer, A., Rödl, R., Stücker, R., and Zilkens, C.
- Published
- 2015
- Full Text
- View/download PDF
34. Pandemic Influenza A (H1N1) Outbreak in 15 School-Aged HIV-Infected Children
- Author
-
Feiterna-Sperling, C, primary, Edelmann, A, additional, Nickel, R, additional, Magdorf, K, additional, Bergmann, F, additional, Rautenberg, P, additional, Schweiger, B, additional, Wahn, V, additional, Krüger, D, additional, and Hofmann, J, additional
- Published
- 2010
- Full Text
- View/download PDF
35. Schwangerschaften HIV-infizierter Frauen 2004–2008
- Author
-
Gingelmaier, A, primary, Kästner, R, additional, Sovric, M, additional, Feiterna-Sperling, C, additional, Notheis, G, additional, Friese, K, additional, and Weizsäcker, K, additional
- Published
- 2009
- Full Text
- View/download PDF
36. Schwangerschaften bei mütterlicher HIV-Infektion an zwei deutschen Schwerpunktzentren 2004–2008
- Author
-
Gingelmaier, A, primary, Kästner, R, additional, Siedentopf, JP, additional, Feiterna-Sperling, C, additional, Notheis, G, additional, and Weizsäcker, K, additional
- Published
- 2009
- Full Text
- View/download PDF
37. Nekrotisierende Enterokolitis bei reifen HIV-exponierten Neugeborenen
- Author
-
Östreicher, I, primary, Feiterna-Sperling, C, additional, Weizsäcker, K, additional, Schmitz, T, additional, Loui, A, additional, and Hüseman, D, additional
- Published
- 2008
- Full Text
- View/download PDF
38. A significan sex—but not elective cesarean section—effect on mother-to-child transmission of hepatitis C virus infection
- Author
-
Amoroso, A., Asensi-Botet, F., Pereda, A., Balossini, V., Bona, G., Zaffaroni, M., Bandelloni, A., Coscia, A., Fabris, C., Aime, S., Belloni, C., Bossi, G., Salati, B., Boucher, C., Buffolano, W., Butler, K., Cabero Roura, L., Bertran Sanges, J. M., Cigna, P., Ciria, L. M., Servera Ginard, C., Claret Teruel, G., Fortuny, C., Coll, O., Corrias, A., Ledda, R., Floris, S., Maria, A., Echeverria, J., Cilla, G., Lanari, M., Tridapalli, E., Venturi, V., Faldella, G., Fischler, B., Bohlin, A. -B, Lindgren, S., Lindh, G., Giacomet, V., Merlo, M., Figini, C., Erba, P., Viganò, A., Hannam, S., Mieli-Vergani, G., Hatzakis, A., Inchley, C., Fjaerli, H. O., Maccabruni, A., Marcellini, M., Sartorelli, M. R., Martin Fontelos, P., Mazza, A., Mok, J. Y. Q., Mûr, A., Viñolas, M., Paternoster, D. M., Grella, P., Polywka, S., Quinti, I., Casadei, A. M., Rojahn, A., Berg, A., Rosso, R., Ferrando, S., Bassetti, D., Ruiz Contreras, J., Manzanares, A., Ruiz Extremera, A., Salvini, F., Gianvincenzo Zuccotti, Schmitz, T., Grosch-Wörner, I., Feiterna Sperling, C., Piening, T., Vegnente, A., Iorio, R., Versace, A., Garetto, S., Lazier, L., Bressio, S., Riva, C., Alfarano, A., Wejstal, R., Norkrans, G., Zanetti, A., Tanzi, E., Tovo, P. -A, Pembrey, L., and Newell, M. -L
39. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West
- Author
-
Giaquinto, C., Rampon, O., D Elia, R., Anita De Rossi, Grosch-Woerner, I., Feiterna-Sperling, C., Schmitz, T., Casteleyn, S., Mok, J., Jose, I., Bates, I., Larru, B., Pena, J. M., Garcia, J. Gonzalez, Lopez, J. R. Arribas, Garcia-Rodriguez, M. C., Asensi-Botet, F., Otero, M. C., Perez-Tamarit, D., Suarez, G., Scherpbier, H., Kreyenbroek, M., Godfried, M. H., Nellen, F. J., Boer, K., Bohlin, A. B., Lindgren, S., Belfrage, E., Naver, L., Anzen, B., Lidman, K., Levy, J., Hainaut, M., Goetghebuer, T., Manigart, Y., Barlow, P., Ferrazin, A., Bassetti, D., Maria, A., Bentivoglio, G., Ferrero, S., Gotta, C., Mur, A., Paya, A., Lopez-Vilchez, M. A., Carreras, R., Valerius, N. H., Jimenez, J., Coll, O., Suy, A., Perez, J. M., Fortuny, C., Boguna, J., Caro, M. Casellas, Canet, Y., Pardi, G., Ravizza, M., Guerra, B., Lanari, M., Bianchi, S., Bovicelli, L., Prati, E., Duse, M., Scaravelli, G., Stegagno, M., Santis, M., Savasi, V., Ferrazzi, E., Vigano, A., Giacomet, V., Probizer, F. Ravagni, Maccabruni, A., Bucceri, A., Rancilio, L., Alberico, S., Rabusin, M., Bernardon, M., Taylor, G. P., Lyall, E. G. H., Penn, Z., Buffolano, W., Tiseo, R., Martinelli, P., Sansone, M., Agangi, A., Tibaldi, C., Marini, S., Masuelli, G., Benedetto, C., Niemiec, T., Marczynska, M., Oldakowska, A., Kaflik, M., Posokhova, S., Kaleeva, T., Stelmah, A., Kiseleva, G., and European Collaborative, Study
40. Treatment and monitoring of children with chronic hepatitis C in the Pre-DAA era: A European survey of 38 paediatric specialists
- Author
-
Indolfi, Giuseppe, Bailey, Heather, Serranti, Daniele, Giaquinto, Carlo, Thorne, Claire, Jahnel, Jörg, Sokal, Etienne, Lamireau, Thierry, Lacaille, Florence, Debray, Dominique, Girard, Muriel, Feiterna‐Sperling, Cornelia, Wirth, Stefan, Vassiliki, Papaevangelou, Dezsofi, Antal, Guidi, Roberto, Verucchi, Gabriella, D'Antiga, Lorenzo, Nicastro, Emanuele, Maggiore, Giuseppe, Trapani, Sandra, Ricci, Silvia, Resti, Massimo, Giacomet, Vania, Benincaso, Anna Rita, Nebbia, Gabriella, Iorio, Raffaele, Cananzi, Mara, Riva, Silvia, Bossi, Grazia, Dodi, Icilio, Nobili, Valerio, Comparcola, Donatella, Garazzino, Silvia, Calvo, Pier Luigi, Pokorska‐Śpiewak, Maria, Pawlowska, Malgorzata, Gonçalves, Cristina, Gonçalves, Isabel, Tudor, Ana Maria, Julian, Antoni Noguera, Hierro, Loreto, Ramos, Jose T., Fischler, Björn, McLin, Valérie, Kansu, Turkey Aydan, Brown, Maxine, Kelly, Deirdre, Davison, Suzanne, Turkova, Anna, Bamford, Alasdair, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Indolfi, G., Bailey, H., Serranti, D., Giaquinto, C., Thorne, C., Sokal, E., Debray, D., Girard, M., Feiterna-Sperling, C., Wirth, S., Guidi, R., Verucchi, G., D'Antiga, L., Nicastro, E., Maggiore, G., Trapani, S., Ricci, S., Resti, M., Giacomet, V., Benincaso, A. R., Nebbia, G., Iorio, R., Cananzi, M., Riva, S., Bossi, G., Dodi, I., Nobili, V., Comparcola, D., Garazzino, S., Calvo, P. L., Pokorska-Spiewak, M., Pawlowska, M., Goncalves, C., Goncalves, I., Bals, M., Tudor, A. M., Noguera-Julian, A., Ramos, J. T., Fischler, B., Mclin, V., Brown, M., Kelly, D., Davison, S., Turkova, A., Bamford, A., Indolfi G., Bailey H., Serranti D., Giaquinto C., Thorne C., Sokal E., Debray D., Girard M., Feiterna-Sperling C., Wirth S., Guidi R., Verucchi G., D'Antiga L., Nicastro E., Maggiore G., Trapani S., Ricci S., Resti M., Giacomet V., Benincaso A.R., Nebbia G., Iorio R., Cananzi M., Riva S., Bossi G., Dodi I., Nobili V., Comparcola D., Garazzino S., Calvo P.L., Pokorska-Spiewak M., Pawlowska M., Goncalves C., Goncalves I., Bals M., Tudor A.M., Noguera-Julian A., Ramos J.T., Fischler B., McLin V., Brown M., Kelly D., Davison S., Turkova A., and Bamford A.
- Subjects
Male ,Pediatrics ,Cirrhosis ,Epidemiology ,medicine.medical_treatment ,Hepacivirus ,Liver transplantation ,medicine.disease_cause ,Direct-acting antivirals ,Liver disease ,0302 clinical medicine ,030212 general & internal medicine ,Europe, direct-acting antivirals, epidemiology, treatment, vertical transmission ,Child ,education.field_of_study ,treatment ,Age Factors ,Europe ,Infectious Diseases ,Child, Preschool ,Vertical transmission ,Female ,030211 gastroenterology & hepatology ,epidemiology ,medicine.medical_specialty ,Adolescent ,Genotype ,Attitude of Health Personnel ,Hepatitis C virus ,Population ,Socio-culturale ,Antiviral Agents ,03 medical and health sciences ,Chronic hepatitis ,Hcv genotype 1 ,Virology ,medicine ,Humans ,Pediatricians ,education ,direct-acting antivirals ,direct-acting antiviral ,Hepatology ,business.industry ,Infant, Newborn ,Infant ,Hepatitis C, Chronic ,medicine.disease ,Treatment ,Cross-Sectional Studies ,Health Care Surveys ,vertical transmission ,business - Abstract
The burden of paediatric HCV infection across Europe is unknown, as are current policies regarding monitoring and treatment. This collaborative study aimed to collect aggregate data to characterise the population of ≤18-year olds with HCV infection in specialist follow up in a twelve-month period (2016) across the PENTAHep European consortium, and investigate current policies around monitoring and treatment. A cross-sectional, web-based survey was distributed in April 2017 to 50 paediatricians in 19 European countries, covering patients' profile, and monitoring and treatment practices. Responses were received from 38/50 clinicians collectively caring for 663 children with chronic HCV infection of whom three-quarters were aged ≥6 years and 90% vertically-infected. HCV genotype 1 was the most common (n 380; 57.3%), followed by genotype 3, 4 and 2. Seventeen children (3%) with chronic HCV infection were diagnosed with cirrhosis and 6 were reported to have received liver transplantation for HCV-related liver disease. The majority (n 425; 64.1%) of the European children with HCV infection remained treatment-naive in 2016. Age affected clinicians' attitudes towards treatment; 94% reported being willing to use direct-acting antivirals, if available, in adolescents (aged ≥11 years), 78% in children aged 6-10 and 42% in those 3 to 5 years of age (Pearson correlation coefficient -0.98; p 0.0001). This survey provides the largest characterisation of the population of children in clinical follow-up for chronic HCV infection in Europe, alongside important contextual information on their management and treatment. Discussion is needed around strategies and criteria for use of direct-acting antivirals in these children. This article is protected by copyright. All rights reserved
- Published
- 2019
41. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with HIV-1 who have not previously been treated: the PENTA 5 randomized trial
- Author
-
J. P. Aboulker, A. Babiker, A. Compagnucci, J. H. Darbyshire, M. Debré, C. Giaquinto, D. M. Gibb, L. Harper, Y. Saidi, AS Walker, J. Darbyshire, D. Johnson, P. Kelleher, L. McGee, A Newberry, A. Poland, A. S. Walker, J P. Aboulker, I. Carrière, V. Eliette, S. Leonardo, M. Gersten, A. Jones, S. Blanche, A. B. Bohlin, K Butler, G. Castelli Gattinara, P. Clayden, R De Groot, A. Faye, C. Griscelli, I Grosch Wörner, C. Kind, H. Lyall, J. Levy, M. Mellado Pena, D. Nadal, C Peckham, J. T. Ramos Amador, L. Rosado, C. Rudin, H. Scherpbier, M Sharland, P. A. Tovo, G. Tudor Williams, N. Valerius, A. Volny Anne, U Wintergerst, V. Wahn, C. Hill, P Lepage, A. Pozniak, S. Vella, M. Hainaut, A. Peltier, S. Carlier, G. Zissis, M. Della Negra, W. Queiroz, L. P. Feitosa, D Oliveira, F. Mechinaud, F. Ballerau, A. Lepelletier, S. Billaudel, V. Ferre, I. Grosch Wörner, R. Weigel, K. Seel, C. Feiterna Sperling, D. Ohlendorf, G. Riße, C. Müller, T. Niehues, J. Ndagijimana, G. Horneff, N. Vente, R. Ganschow, T. Simon, R. Vossen, H Pfister, U. Wintergerst, G. Notheis, G. Strotmann, S Schlieben, K. Butler, E. Hayes, M. O’Mara, J. Fanning, F. Goggins, S. Moriarty, M. Byrne, L. Battisti, M. Duse, S. Timpano, E. Uberti, P. Crispino, P. Carrara, F. Fomia, A. Manca, L. Galli, M. de Martino, F. Fioredda, E. Pontali, M. Cellini, C. Baraldi, M. Portolani, M. Meacci, P. Pietrosemoli, R. Berni Canani, P. Laccetti, M. Gobbo, V. Giacomet, R. D’Elia, O. Rampon, E. Ruga, A. de Rossi, M. Zanchetta, D. Caselli, A. Maccabruni, E. Cattaneo, V Landini, S. Bernardi, A. Krzysztofiak, C. Tancredi, P. Rossi, L. Pansani, E. Palomba, C. Gabiano, A. Mazza, G. Rossetti, R. Nicolin, A. Timillero, F. Candeias, G Santos, M. L. Ramos Ribeiro, M. C. Almeida, M. H. Lourenço, R. Antunes, M. J. Mellado Pena, M L. Carillo de Albornoz, P. Martinez Santos, L. Ciria Calavia, J. Serra Devecchi, O. Delgado, N. Matamoros, A. Foot, H. Kershaw, C. Kelly, O. Caul, W. Tarnow Mordi, J. Petrie, A. McDowell, P. McIntyre, K. Appleyard, K. Sloper, V. Shah, K. Cheema, A. Aali, J. Mok, R. Russell, A. Brewster, N. Richardson, S. Burns, D. Gibb, V. Novelli, N. Klein, S. Ewen, V. Yeung, C. Ball, K. Himid, D. Nayagam, D. Graham, A. Barrie, K. Stringer, S. Jones, N. Weerasooriya, M. Zuckerman, P. Bracken, E. Cooper, T. Fisher, R. Barrie, U. Patel, V. Van Someren, K. Moshal, L. Perry, T. Gundlach, J. Norman, M. Sharland, M. Richardson, S. Donaghy, Z. Mitchla, C. Wells, J. Booth, A. Shipp, J. White, S. Head, S. Lambers, K. O’Hara, C. Stainsby, G. Du Mont, T. Solanki, S. Swanton, S. O’Shea, A. Tilsey, S. Kaye, A. Finn, S. Choo, R. Lakshman, L. Barr, G. Bell, A. Siddens, GUARINO, ALFREDO, SPAGNUOLO, MARIA IMMACOLATA, Aboulker, J. P., Babiker, A., Compagnucci, A., Darbyshire, J. H., Debré, M., Giaquinto, C., Gibb, D. M., Harper, L., Saidi, Y., Walker, A, Darbyshire, J., Johnson, D., Kelleher, P., Mcgee, L., Newberry, A, Poland, A., Walker, A. S., Aboulker, J P., Carrière, I., Eliette, V., Leonardo, S., Gersten, M., Jones, A., Blanche, S., Bohlin, A. B., Butler, K, Castelli Gattinara, G., Clayden, P., R De Groot, Faye, A., Griscelli, C., I Grosch Wörner, Kind, C., Lyall, H., Levy, J., Mellado Pena, M., Nadal, D., Peckham, C, Ramos Amador, J. T., Rosado, L., Rudin, C., Scherpbier, H., Sharland, M, Tovo, P. A., Tudor Williams, G., Valerius, N., Volny Anne, A., Wintergerst, U, Wahn, V., Hill, C., Lepage, P, Pozniak, A., Vella, S., Hainaut, M., Peltier, A., Carlier, S., Zissis, G., Della Negra, M., Queiroz, W., Feitosa, L. P., Oliveira, D, Mechinaud, F., Ballerau, F., Lepelletier, A., Billaudel, S., Ferre, V., Grosch Wörner, I., Weigel, R., Seel, K., Feiterna Sperling, C., Ohlendorf, D., Riße, G., Müller, C., Niehues, T., Ndagijimana, J., Horneff, G., Vente, N., Ganschow, R., Simon, T., Vossen, R., Pfister, H, Wintergerst, U., Notheis, G., Strotmann, G., Schlieben, S, Butler, K., Hayes, E., O’Mara, M., Fanning, J., Goggins, F., Moriarty, S., Byrne, M., Battisti, L., Duse, M., Timpano, S., Uberti, E., Crispino, P., Carrara, P., Fomia, F., Manca, A., Galli, L., de Martino, M., Fioredda, F., Pontali, E., Cellini, M., Baraldi, C., Portolani, M., Meacci, M., Pietrosemoli, P., Guarino, Alfredo, Spagnuolo, MARIA IMMACOLATA, Berni Canani, R., Laccetti, P., Gobbo, M., Giacomet, V., D’Elia, R., Rampon, O., Ruga, E., de Rossi, A., Zanchetta, M., Caselli, D., Maccabruni, A., Cattaneo, E., Landini, V, Bernardi, S., Krzysztofiak, A., Tancredi, C., Rossi, P., Pansani, L., Palomba, E., Gabiano, C., Mazza, A., Rossetti, G., Nicolin, R., Timillero, A., Candeias, F., Santos, G, Ramos Ribeiro, M. L., Almeida, M. C., Lourenço, M. H., Antunes, R., Mellado Pena, M. J., Carillo de Albornoz, M L., Martinez Santos, P., Ciria Calavia, L., Serra Devecchi, J., Delgado, O., Matamoros, N., Foot, A., Kershaw, H., Kelly, C., Caul, O., Tarnow Mordi, W., Petrie, J., Mcdowell, A., Mcintyre, P., Appleyard, K., Sloper, K., Shah, V., Cheema, K., Aali, A., Mok, J., Russell, R., Brewster, A., Richardson, N., Burns, S., Gibb, D., Novelli, V., Klein, N., Ewen, S., Yeung, V., Ball, C., Himid, K., Nayagam, D., Graham, D., Barrie, A., Stringer, K., Jones, S., Weerasooriya, N., Zuckerman, M., Bracken, P., Cooper, E., Fisher, T., Barrie, R., Patel, U., Van Someren, V., Moshal, K., Perry, L., Gundlach, T., Norman, J., Sharland, M., Richardson, M., Donaghy, S., Mitchla, Z., Wells, C., Booth, J., Shipp, A., White, J., Head, S., Lambers, S., O’Hara, K., Stainsby, C., Du Mont, G., Solanki, T., Swanton, S., O’Shea, S., Tilsey, A., Kaye, S., Finn, A., Choo, S., Lakshman, R., Barr, L., Bell, G., and Siddens, A.
- Abstract
Introduction Treatment options for children with HIV-1 are limited. We aimed to compare activity and safety of three dualnucleoside analogue reverse-transcriptase inhibitor (NRTI) regimens with or without a protease inhibitor in previously untreated children with HIV-1. Methods In our multicentre trial, we randomly assigned 36 children to zidovudine and lamivudine, 45 to zidovudine and abacavir, and 47 to lamivudine and abacavir. Children who were symptomfree (n=55) were also randomly assigned to receive nelfinavir or placebo. Children with more advanced disease received open-label nelfinavir (73). Primary endpoints were change in plasma HIV-1 RNA at 24 and 48 weeks for the NRTI comparison and occurrence of serious adverse events for both randomised comparisons. Analyses were by intention to treat. Findings Children had a median CD4 percentage of 22% (IQR 15–29) and a mean HIV-1 RNA concentration of 5·0 log copies/mL (SD 0·8). One child was lost to follow-up and one died of sepsis. At 48 weeks, in the zidovudine/lamivudine, zidovudine/abacavir, and lamivudine/abacavir groups, mean HIV-1 RNA had decreased by 1·71, 2·19, and 2·63 log copies/mL, respectively (estimated in absence of nelfinavir) (p=0·02 after adjustment for baseline factors). One child had a hypersensitivity reaction to abacavir; and three with possible reactions stopped abacavir. There were 24 serious adverse events—six in the symptom-free children (all on nelfinavir), but none were attributed to nelfinavir. Interpretation Regimens containing abacavir were more effective than zidovudine/lamivudine. Such regimens could be combined with protease inhibitors and non-nucleoside reverse transcriptase inhibitors for safe and effective treatment of previously untreated children with HIV-1.
- Published
- 2002
42. Efficacy and safety of 2-drug regime dolutegravir/lamivudine in pregnancy and breastfeeding - clinical implications and perspectives.
- Author
-
Rohr I, Hoeltzenbein M, Weizsäcker K, Weber C, Feiterna-Sperling C, and Metz CK
- Abstract
Objectives: To assess the efficacy and safety of a two-drug regimen (2DR) with dolutegravir (DTG) and lamivudine (3TC) in maintaining viral suppression during pregnancy and breastfeeding, and to evaluate its potential as an alternative to the recommended three-drug regimen (3DR) in preventing mother-to-child transmission (MTCT) of HIV., Methods: We present a case of a 34-year-old pregnant woman who, after discontinuing 3DR due to side effects and poor adherence, was switched to DTG/3TC at gestational week 23. Maternal viral load (VL) and infant HIV status were monitored throughout pregnancy and a ten-month breastfeeding period. Data on pharmacokinetic changes in pregnancy and the risks associated with 2DR were reviewed., Results: The patient's VL remained suppressed (<20 copies/mL) from gestational week 23 until the end of the breastfeeding period. A healthy HIV-negative baby was born at 39 weeks, and the child remained HIV-negative after ten months of breastfeeding. The 2DR was well-tolerated, improved adherence, and reduced fetal drug exposure. Despite limited experience with 2DR in pregnancy, no viral rebound occurred, and no adverse effects were observed., Conclusions: Although 3DR remains the preferred therapy during pregnancy and breastfeeding, this case indicates that DTG/3TC may be an effective alternative for patients experiencing intolerance or poor adherence to 3DR. Further studies are needed to explore the impact of pharmacokinetic changes in pregnancy on 2DR efficacy and to confirm its safety and role in preventing MTCT., (© 2024 Walter de Gruyter GmbH, Berlin/Boston.)
- Published
- 2024
- Full Text
- View/download PDF
43. Prenatal ultrasound screening and pregnancy outcomes in HIV-positive women in Germany: results from a retrospective single-center study at the Charité-Universitätsmedizin Berlin.
- Author
-
Hofacker M, Weichert A, Feiterna-Sperling C, von Weizsäcker K, Siedentopf JP, Heinrich-Rohr M, Henrich W, and Rohr I
- Subjects
- Humans, Female, Pregnancy, Retrospective Studies, Adult, Infant, Newborn, Germany epidemiology, Cesarean Section statistics & numerical data, Congenital Abnormalities diagnostic imaging, Congenital Abnormalities epidemiology, Young Adult, Infectious Disease Transmission, Vertical prevention & control, Infectious Disease Transmission, Vertical statistics & numerical data, Pregnancy Complications, Infectious epidemiology, HIV Infections drug therapy, Ultrasonography, Prenatal statistics & numerical data, Pregnancy Outcome
- Abstract
Objectives: The aim of this study was to investigate the rate of Mother-to-child-transmission (MTCT) in women living with HIV (WLWH) in a tertiary care institution. Furthermore, we aimed to assess prenatal ultrasound screening for fetal anomalies and outcomes in high-risk pregnancies due to maternal HIV infection.", Methods: In this single-center study, retrospective data related to pregnancy and childbirth were collected from 420 WLWH. All data were evaluated descriptively., Results: From January 2014 to December 2020, a total number of 420 pregnant WLWH delivered 428 newborns. 415 (98.8%) were receiving antiretroviral therapy (ART) and 88.8% had a viral load of < 50 cop/ml prior delivery. 46 (11%) of the newborns were born prematurely. Low birth weight < 2500 g occurred in 38 (9.1%) of the children. 219 (52.1%) caesarean sections (CS) were performed. The most frequent indication for an elective CS was a previous CS (70.2%). 8 severe malformations were detected using first and second trimester ultrasound. In one child, MTCT was detected postpartum, resulting in an HIV transmission rate of 0.2% in the presented cohort., Conclusions: The low rate of vertical HIV-transmission in our cohort of 0.2% is the result of interdisciplinary prenatal care and high experience of healthcare providers in treatment of WLWH. Despite high ART coverage and adherence, good maternal immune system and very low vertical HIV transmission rate, maternal HIV infection remains a challenge in obstetric care. First and second ultrasound screening should be a part of prenatal care for HIV-infected women and should also be offered to HIV-negative women. A reduction of the rate of unnecessary elective caesarean deliveries in WLWH is necessary to reduce complications in subsequent pregnancies., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
44. Tuberculosis Disease in Immunocompromised Children and Adolescents: A Pediatric Tuberculosis Network European Trials Group Multicenter Case-control Study.
- Author
-
Rodríguez-Molino P, Tebruegge M, Noguera-Julian A, Neth O, Fidler K, Brinkmann F, Sainz T, Ivaskeviciene I, Ritz N, Brito MJ, Milheiro Silva T, Chechenieva V, Serdiuk M, Lancella L, Russo C, Soler-García A, Navarro ML, Krueger R, Feiterna-Sperling C, Starshinova A, Hiteva A, Hoffmann A, Kalibatas P, Lo Vecchio A, Scarano SM, Bustillo M, Blázquez Gamero D, Espiau M, Buonsenso D, Falcón L, Turnbull L, Colino E, Rueda S, Buxbaum C, Carazo B, Alvarez C, Dapena M, Piqueras A, Velizarova S, Ozere I, Götzinger F, Pareja M, Garrote Llanos MI, Soto B, Rodríguez Martín S, Korta JJ, Pérez-Gorricho B, Herranz M, Hernández-Bartolomé Á, Díaz-Almirón M, Kohns Vasconcelos M, Ferreras-Antolín L, and Santiago-García B
- Subjects
- Humans, Case-Control Studies, Child, Male, Female, Adolescent, Europe epidemiology, Child, Preschool, Infant, Tuberculin Test, Antitubercular Agents therapeutic use, Immunocompromised Host, Tuberculosis epidemiology, Tuberculosis diagnosis
- Abstract
Background: In high-resource settings, the survival of children with immunocompromise (IC) has increased and immunosuppressive therapies are increasingly being used. This study aimed to determine the clinical characteristics, performance of diagnostic tools, and outcome of IC children with tuberculosis (TB) in Europe., Methods: Multicenter, matched case-control study within the Pediatric Tuberculosis Network European Trials Group, capturing TB cases <18 years diagnosed 2000-2020., Results: A total of 417 TB cases were included, comprising 139 children who are IC (human immunodeficiency virus, inborn errors of immunity, drug-induced immunosuppression, and other immunocompromising conditions) and 278 non-IC children as controls. Nonrespiratory TB was more frequent among cases than controls (32.4% vs 21.2%; P = .013). Patients with IC had an increased likelihood of presenting with severe disease (57.6% vs 38.5%; P < .001; odds ratio [95% confidence interval], 2.073 [1.37-3.13]). Children with IC had higher rates of false-negative tuberculin skin test (31.9% vs 6.0%; P < .001) and QuantiFERON-TB Gold assay (30.0% vs 7.3%; P < .001) results at diagnosis. Overall, the microbiological confirmation rate was similar in IC and non-IC cases (58.3% vs 49.3%; P = .083). Although the mortality in children with IC was <1%, the rate of long-term sequelae was significantly higher than in non-IC cases (14.8% vs 6.1%; P = .004)., Conclusions: Children with IC and TB in Europe have increased rates of nonrespiratory TB, severe disease, and long-term sequelae. Immune-based TB tests have poor sensitivity in those children. Future research should focus on developing improved immunological TB tests that perform better in patients with IC, and determining the reasons for the increased risk of long-term sequelae, with the aim to design preventive management strategies., Competing Interests: Potential conflicts of interest . B. S. G. and M. T. have received support from Cepheid for a project on molecular tuberculosis diagnostics unrelated to the study reported here. M. T. has received QuantiFERON-TB assays at reduced pricing or free of charge for tuberculosis diagnostics projects from Cellestis/Qiagen in the past and has received support for conference attendance from Cepheid. The manufacturers had no influence on the study design, data collection, analysis or interpretation, writing of the manuscript, or the decision to submit the data for publication. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
45. Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland.
- Author
-
Otto-Knapp R, Bauer T, Brinkmann F, Feiterna-Sperling C, Friesen I, Geerdes-Fenge H, Hartmann P, Häcker B, Heyckendorf J, Kuhns M, Lange C, Maurer FP, Nienhaus A, Priwitzer M, Richter E, Salzer HJF, Schoch OD, Schönfeld N, and Schaberg T
- Subjects
- Humans, Austria, Diarylquinolines pharmacology, Diarylquinolines therapeutic use, Germany, Linezolid pharmacology, Linezolid therapeutic use, Moxifloxacin pharmacology, Moxifloxacin therapeutic use, Switzerland, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Extensively Drug-Resistant Tuberculosis drug therapy, Rifampin pharmacology, Rifampin therapeutic use, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB) in December 2022. The new recommendations and the latest study data made it necessary to update the existing guideline on the treatment of at least rifampicin-resistant TB (RR-TB) for the German-speaking countries, replacing the respective chapters of the treatment guidelines published in 2022. A shortened treatment of proven RR-TB and multidrug-resistant TB for at least 6 months using the fixed and non-modifiable drug combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is now also recommended for Austria, Germany, and Switzerland under certain conditions considering the existing barriers for the implementation of the new treatment regimen. For the treatment of pre-extensively drug-resistant (pre-XDR-) TB, an individualized treatment for 18 months continues to be the primary recommendation. The non-modifiable drug combination of bedaquiline, pretomanid, and linezolid (BPaL) may be used alternatively in selected pre-XDR-TB cases, provided that all prerequisites are met. The necessary requirements for using BPaLM and BPaL are presented in detail in this amendment to the consensus-based TB treatment guideline for adult patients., (© 2024 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
46. [Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)].
- Author
-
Otto-Knapp R, Bauer T, Brinkmann F, Feiterna-Sperling C, Friesen I, Geerdes-Fenge H, Hartmann P, Häcker B, Hauer B, Haas W, Heyckendorf J, Kuhns M, Lange C, Maurer FP, Nienhaus A, Priwitzer M, Richter E, Salzer HJF, Schoch O, Schönfeld N, and Schaberg T
- Subjects
- Humans, Rifampin, Antitubercular Agents therapeutic use, Linezolid therapeutic use, Austria, Switzerland, Germany, Drug Combinations, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis drug therapy, Nitroimidazoles
- Abstract
In December 2022, based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB). The evaluation of both, these recommendations, and the latest study data, makes it necessary to update the existing guidelines on the treatment of at least rifampicin-resistant tuberculosis for the German-speaking region, hereby replacing the respective chapters. A shortened MDR-TB treatment of at least 6 month using the fixed and non-modifiable drug combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is now also recommended for Germany, Austria, and Switzerland under certain conditions. This recommendation applies to TB cases with proven rifampicin resistance, including rifampicin monoresistance. For treatment of pre-extensively drug resistant TB (pre-XDR-TB), an individualized treatment for 18 months adjusted to resistance data continues to be the primary recommendation. The non-modifiable drug combination of bedaquiline, pretomanid, and linezolid (BPaL) may be used alternatively in pre-XDR TB if all prerequisites are met. The necessary prerequisites for the use of BPaLM and BPaL are presented in this amendment to the S2k guideline for 'Tuberculosis in adulthood'., Competing Interests: Informationen zu Interessenkonflikten finden Sie auf den Seiten der AWMF (http://www.awmf.org/leitlinien/awmf-regelwerk.html)., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Performance of QuantiFERON-TB Gold Plus assays in paediatric tuberculosis: a multicentre PTBNET study.
- Author
-
Buonsenso D, Noguera-Julian A, Moroni R, Hernández-Bartolomé A, Fritschi N, Lancella L, Cursi L, Soler-Garcia A, Krüger R, Feiterna-Sperling C, Sali M, Lo Vecchio A, Scarano S, Hernanz Lobo A, Espiau M, Soriano-Arandes A, Cetin BS, Brinkmann F, Ozere I, Baquero-Artigao F, Tsolia M, Milheiro Silva T, Bustillo-Alonso M, Martín Nalda A, Mancini M, Starshinova A, Ritz N, Velizarova S, Ferreras-Antolín L, Götzinger F, Bilogortseva O, Chechenyeva V, Tebruegge M, and Santiago-García B
- Subjects
- Humans, Child, Child, Preschool, Cohort Studies, Interferon-gamma Release Tests methods, Tuberculin Test methods, Europe, Tuberculosis diagnosis, Latent Tuberculosis diagnosis
- Abstract
Rationale: In 2016, a new interferon-gamma release assay (IGRA) was introduced, QuantiFERON-TB Gold Plus (QFT-Plus), claimed to have improved sensitivity in active tuberculosis (TB)., Objectives: This study aimed to determine the performance of QFT-Plus, compared with previous generation IGRAs and the tuberculin skin test (TST), in children with TB in Europe., Methods: Multicentre, ambispective cohort study within the Paediatric Tuberculosis Network European Trials Group (ptbnet), a dedicated paediatric TB research network comprising >300 members, capturing TB cases <18 years-of-age diagnosed between January 2009 and December 2019., Measurements and Main Results: 1001 TB cases from 16 countries were included (mean age (IQR) 5.6 (2.4-12.1) years). QFT-Plus was performed in 358, QFT Gold in-Tube (QFT-GIT) in 600, T-SPOT. TB in 58 and TST in 636 cases. The overall test sensitivities were: QFT-Plus 83.8% (95% CI 80.2% to 87.8%), QFT-GIT 85.5% (95% CI 82.7% to 88.3%), T-SPOT. TB 77.6% (95% CI 66.9% to 88.3%) and TST (cut-off ≥10 mm) 83.3% (95% CI 83.3% to 86.2%). There was a trend for tests to have lower sensitivity in patients with miliary and/or central nervous system (CNS) TB (73.1%, 70.9%, 63.6% and 43.5%, respectively), and in immunocompromised patients (75.0%, 59.6%, 45.5% and 59.1%, respectively)., Conclusions: The results indicate that the latest generation IGRA assay, QFT-Plus, does not perform better than previous generation IGRAs or the TST in children with TB disease. Overall, tests performed worse in CNS and miliary TB, and in immunocompromised children. None of the tests evaluated had sufficiently high sensitivity to be used as a rule-out test in children with suspected TB., Competing Interests: Competing interests: DB participated in a Qiagen advisory board meeting on the use of IGRAs in children <5 years of age. The manufacturers had no influence on the study design, data collection, analysis or interpretation, writing of the manuscript or the decision to submit the data for publication. BS-G and MT have received support from Cepheid for a project on molecular TB diagnostics unrelated to the study reported here. MT has received QuantiFERON-TB assays at reduced pricing or free of charge for TB diagnostics projects from the manufacturer (Cellestis/Qiagen) in the past, and has received support for conference attendance from Cepheid., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
48. Refugees from Ukraine: children and adolescents with HIV in Germany.
- Author
-
Feiterna-Sperling C, Bethke H, Hofmann J, and Krüger R
- Subjects
- Humans, Child, Adolescent, Ukraine epidemiology, Germany, HIV Infections epidemiology, Refugees
- Abstract
Competing Interests: We declare no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
49. [Tuberculosis-Update 2022].
- Author
-
Kainz K, Brinkmann F, Bogyi M, Feiterna-Sperling C, Götzinger F, Mädel C, Thee S, and Krüger R
- Abstract
According to the annual global reports from the Word Health Organization (WHO), children under 15 years of age represent 11% of all cases of tuberculosis (TB) globally. Nearly 50% of these cases are children below 5 years old. This continuing medical education (CME) article provides an overview of the current recommendations and innovations based on the revised WHO guidelines on TB management in children and adolescents published in 2022., (© The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2023.)
- Published
- 2023
- Full Text
- View/download PDF
50. [Tuberculosis in adulthood - The Sk2-Guideline of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of adult tuberculosis patients].
- Author
-
Schaberg T, Brinkmann F, Feiterna-Sperling C, Geerdes-Fenge H, Hartmann P, Häcker B, Hauer B, Haas W, Heyckendorf J, Lange C, Maurer FP, Nienhaus A, Otto-Knapp R, Priwitzer M, Richter E, Salzer HJF, Schoch O, Schönfeld N, Stahlmann R, and Bauer T
- Subjects
- Adult, Humans, Antitubercular Agents therapeutic use, Germany, Tuberculosis diagnosis, Tuberculosis prevention & control, HIV Infections, Latent Tuberculosis
- Abstract
In Germany tuberculosis is a rare disease and usually well treatable. Worldwide it is one of the most common infectious diseases with approximately 10 million new cases every year. Even with low incidences in Germany, tuberculosis is an important differential diagnosis especially due to international developments and migration movements. With a decreasing experience there's a continuous demand on accurate and up-to-date information. This guideline covers all aspects of microbiological diagnostics, basic principles of standard therapy, treatment of extrapulmonary tuberculosis, management of side effects, special features of diagnosis and treatment of resistant tuberculosis, and treatment in TB-HIV coinfection. Also, it explains when treatment in specialized centers is required, aspects of care and legal regulations and the diagnosis and preventive therapy of latent tuberculosis infection. The update of the S2k guideline "Tuberculosis in Adults" is intended to serve as a guideline for prevention, diagnosis, and treatment of tuberculosis for all those involved in tuberculosis care and to help meet the current challenges in dealing with tuberculosis in Germany., Competing Interests: Eine Übersicht der Interessenkonflikte findet sich im Internet unter http://awmf.org; AWMF-Registriernummer 020-019, (Thieme. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.